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Vascular diseases are a leading cause of morbidity and mortality world-wide.
Understanding their pathogenesis is crucial to better diagnosis and management of
these life-threatening conditions. Through the study of rare mutations that lead to
early onset and severe vascular diseases, we can elucidate underlying mechanisms
for vascular disease pathogenesis and develop better treatments to prevent and
manage more common causes of vascular diseases. In this study we look at two
rare diseases that lead to severe vascular phenotypes, Smooth Muscle Dysfunction
Syndrome (SMDS) and Majewski Osteodysplastic Primordial Dwarfism Type II
(MOPDII). SMDS is a rare condition due to pathogenic variants in ACTA2 p.Arg179,
which lead to dysfunction of smooth muscle cells (SMCs) throughout the body.
Complications of SMDS include early-onset thoracic aortic aneurysms and
dissections, moyamoya-like cerebrovascular disease, patent ductus arteriosus,
pulmonary hypertension and poorly characterized pulmonary disease,
hypoperistalsis of the gut, hypotonic bladder, and congenital mydriasis. Here lung
and liver pathology findings from two infants and one adult with SMDS are
described, including thickening of the terminal branches of the hepatic artery and
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emphysematous pulmonary changes, along with previously described changes
consistent with pulmonary arterial hypertension. These data provide further insight
into the pathophysiology of complications of SMDS. MOPDII is due to homozygous
loss-of-function mutations in PCNT, which lead to primordial dwarfism and early
onset occlusive vascular disease, including moyamoya disease and coronary artery
disease. We examine the pathogenic mechanisms of vascular disease in MOPDII
using a novel SMC-specific pericentrin knock-out mouse line (PcntSMKO). Using this
mouse model, we identify increased proliferation of SMCs explanted from the aortas
of PcntSMKO mice and activation of the ataxia telangiectasia and rad3 related (ATR)
cell cycle regulation pathway. Further, we identify phenotypic modulation of PcntSMKO
SMCs in vitro to a phenotype similar to that observed with the progression of
atherosclerosis in mice. The modulated cells express markers of both macrophages
and fibroblasts, with a reduction in SMC identity markers. This phenotypic
modulation in PcntSMKO SMCs is associated with activation of the unfolded protein
response and cytosolic stress pathways. The findings presented here suggest
potential mechanisms and future targets for vascular disease intervention.
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Chapter 1: Vascular Smooth Muscle Cells and Genetically-Triggered Vascular
Disease

1

The Artery Wall
Artery walls are composed of three main layers, from outside to in: the tunica
adventitia, tunica media, and tunica intima (figure 1.1) (Milewicz et al., 2008; ElHamamsy and Yacoub, 2009). The tunica adventitia lies outside the external elastic
lamina and is comprised primarily of fibroblasts in a collagen-rich extracellular
matrix, which functions to help prevent vessel rupture (Milewicz et al., 2008; ElHamamsy and Yacoub, 2009). In larger arteries such as the aorta, the adventitial
layer also contains vaso vasorum, small arteries which provide oxygen and nutrients
to the outer layers of the vessel wall (El-Hamamsy and Yacoub, 2009). The tunica
media is a thick layer comprised primarily of vascular smooth muscle cells (Milewicz
et al., 2008; El-Hamamsy and Yacoub, 2009). Finally, the tunica intima is comprised
of a single layer of endothelial cells on a basement membrane of collagen (Milewicz
et al., 2008; El-Hamamsy and Yacoub, 2009; Wagenseil and Mecham, 2009).

Figure 1.1. Layers of the artery wall. The artery wall consists of three layers,
the inner most layer, the intima, lies closest to the artery lumen (A). Going
outward, this is followed by the internal elastic lamina (C, red arrow) and then
the medial layer made up of SMCs. In elastic arteries, such as the aorta, the
SMCs are interposed with multiple layers of elastic fibers (A, inset). This is
followed by the external elastic lamina (C, white arrow), and finally the
outermost layer, the adventitia (A). In different disease states a neointima
can form, extending into the vessel lumen (C). [Used with permission from
Milewicz et al, Genetics in Medicine, 2010.]
2

Vascular smooth muscle cells (SMCs) normally reside primarily in the medial
layer where they function to control peripheral blood pressure through their ability to
contract and relax (Milewicz et al., 2017). In addition, SMCs produce extracellular
matrix components, including collagen, elastin, fibrillin and fibulin, which provide
resistance to the high pressures of circulating blood (El-Hamamsy and Yacoub,
2009; Frismantiene et al., 2018). Collagen provides tensile strength to the media and
adventitia to resist vessel rupture, while elastin allows the artery wall to stretch,
distributing pressure and retaining the overall vessel shape (El-Hamamsy and
Yacoub, 2009). In turn, elastin interacts with SMCs to regulate cytoskeletal structure
by inhibiting the SMC proliferative, synthetic phenotype, keeping them in a
differentiated, contractile state (El-Hamamsy and Yacoub, 2009; Milewicz et al.,
2010a). Elastin content differentiates two main artery types, elastic arteries and
muscular arteries. Large elastic arteries, such as the aorta, have a medial layer
made up of alternating layers of elastin and SMCs lined up end-to-end. Muscular
arteries, such as those in the brain, contain only two elastin layers separating the
adventitia from the media, the external elastic lamina, and the media from the intima,
the internal elastic lamina. Those arteries most proximal to the heart tend to be
elastic with a medial layer comprised of vascular smooth muscle cells sandwiched
between layers of elastin fibers and surrounded by extracellular matrix proteins
(Milewicz et al., 2008; El-Hamamsy and Yacoub, 2009). Through these lamellar
units, the medial layer provides tensile strength and elastic recoil to the vessel wall
allowing it to distribute the force of blood flow and retain its shape (Milewicz et al.,
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2008; El-Hamamsy and Yacoub, 2009). Moving distally from the heart, arteries
transition from elastic to muscular (Yu and Mceniery, 2020).
Within the medial layer, SMCs form an elastin-contractile unit through
connection with elastin fibers surrounded by microfibrils (Karimi and Milewicz, 2016).
On the surface of SMCs are focal adhesion complexes through which microfibrils
bind to integrin receptors on the cell surface (Karimi and Milewicz, 2016). These
focal adhesion complexes in turn link to the SMC contractile filaments inside the cell
(Karimi and Milewicz, 2016). These SMC elastin-contractile serve to transmit forces
from the elastin fibers to the SMC (Karimi and Milewicz, 2016).
Genetically-Triggered Vascular Disease
Cardiovascular disease is currently the most common cause of death
worldwide (Francula-Zaninovic and Nola, 2018; Frismantiene et al., 2018; Arnett et
al., 2019). Coronary artery disease and stroke, both a result of pathologic narrowing
of the vessel lumen, account for most of these deaths (Frismantiene et al., 2018).
Commmon risk factors for cardiovascular disease include some invariable factors
such as age and family history, and variable risk factors, including smoking, level of
physical activity, hypertension, obesity, hyperlipidemia, and diabetes mellitus
(Francula-Zaninovic and Nola, 2018).
Vascular disease that is early-onset and arises independently of risk factors
known to lead to cardiovascular disease may be genetically-triggered. Single gene
mutations have been identified that predispose to vascular pathology, including
coronary artery disease, stroke, aortic aneurysms and dissections, cerebral
aneurysms, and Moyamoya disease. Some of these mutations will be discussed in
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the sections below. By studying these rare genetic variants, we are not only able to
identify pathways important to these rare diseases, but also to delineate the cellular
pathways underlying more common causes of vascular pathology. Genes affecting
each layer and cell type of the artery wall have been identified (Munot et al., 2011).
For the purpose of these studies, we focused on mutations in two genes that cause
diffuse and diverse vascular pathology, ACTA2 and PCNT.
I. Thoracic Aortic Aneurysms and Dissections
Thoracic aortic aneurysms and dissections (TAAD) describe a group of
conditions affecting the large, main artery emanating from the heart, the aorta. TAAD
accounts for 43,000 to 47,000 deaths worldwide each year (Pinard et al., 2019). The
pathologic hallmark of this set of conditions is termed “medial degeneration”,
characterized by the loss or fragmentation of elastic fibers and accumulation of
proteoglycan in the medial layer of the aortic wall (Milewicz et al., 2008). As
depicted in figure 1.2, TAAD can affect either the ascending aorta, descending aorta,
or both (Milewicz et al., 2008). Dissection is often, but not always, preceded by
aneurysmal expansion of the artery wall. Dissection occurs when a break or opening
develops in the vessel wall allowing blood into a false lumen which can obstruct flow
through the vessel or rupture leading to hemorrhage.
Multiple genetic syndromes can predispose individuals to TAAD, including
Marfan syndrome caused by mutations in FBN1, Loeys-Dietz syndromes caused by
mutations in TGF-β2 (TGFB2) and its receptors (TGFBR1 and TGFBR2), and the
vascular form of Ehlers-Danlos syndrome caused by mutations in COL3A1, but they
account for only 5% of cases (Byers et al., 1981; Mizuguchi et al., 2004; Loeys et al.,
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2006; Boileau et al., 2012; Faggion Vinholo et al., 2019; Pinard et al., 2019). At least
20% of non-syndromic TAAD is due to an autosomal dominantly inherited genetic
predisposition with decreased penetrance and a variable degree of expression
(Albornoz et al., 2006; Guo et al., 2007). Some of the genes involved in nonsyndromic TAAD include genes related to the extracellular matrix, such as LOX
(Guo et al., 2016; Faggion Vinholo et al., 2019). Genes encoding structural proteins
in the SMC contractile unit are also associated with TAAD, including ACTA2,
MYH11, MYLK, and PRKG1 (Zhu et al., 2006; Seol et al., 2010; Guo et al., 2013;
Karimi and Milewicz, 2016; Pinard et al., 2019).
II. Moyamoya Disease
Moyamoya refers to a rare cerebrovascular condition in which there is
progressive stenosis or narrowing of the intracerebral internal carotid arteries and
their proximal branches predisposing to ischemic stroke [Scott and Smith, 2009].
Under normal conditions, these arterial changes in turn lead to the formation of
compensatory collateral vessels which look like a “puff of smoke” on cerebral
angiogram, from which the name “moyamoya” is derived (Scott and Smith, 2009).
Those individuals who have a characteristic vasculopathy in the setting of a
condition known to be associated with moyamoya are said to have moyamoya
syndrome (Scott and Smith, 2009; Guey et al., 2015). While those individuals with
no known risk factors are characterized as having moyamoya disease, which is
thought to be multifactorial and polygenic (Scott and Smith, 2009; Guey et al., 2015).
Genetic factors are strongly suspected in Moyamoya Disease based on 10%
of cases being familial, a high rate of disease concordance in monozygotic twins and
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a strong ethnicity-related effect (Guey et al., 2015). RNF213 was the first Moyamoya
Disease susceptibility gene identified in patients of Japanese descent (Kamada et
al., 2011; Liu et al., 2011). Alternatively, genes have been associated with
Moyamoya Syndrome leading to moyamoya angiopathy with other neurological
and/or non-neurological findings (Guey et al., 2015). These include recessive Xlinked loss of expression of BRCC3/MTCP1 leading to a syndrome of bilateral
moyamoya angiopathy, short stature, facial dysmorphism, cardiomyopathy, and
hypergonadotropic hypogonadism (Hervé et al., 2010; Miskinyte et al., 2011; Guey
et al., 2015). Another identified syndrome due to mutations in GUCY1A3 associated
with unilateral or bilateral moyamoya angiopathy in addition to achalasia leading to
regurgitation, arterial hypertension, vasomotor dysfunction, erectile dysfunction, and
low platelet count (Hervé et al., 2014; Guey et al., 2015). Finally, some mutations in
ACTA2, including those leading to Smooth Muscle Dysfunction Syndrome are
associated with a moyamoya-like angiopathy associated with diffuse smooth muscle
cell abnormalities, including hypotonic bladder, aortic aneurysm and dissection, and
pulmonary abnormalities (Guo et al., 2009; Milewicz et al., 2010b; Munot et al.,
2012).
III. Coronary Artery Disease
Coronary artery disease (CAD) is characterized by the build-up of
atherosclerotic plaque within the coronary arteries, the vessels supplying blood flow
to the heart (Khera and Kathiresan, 2017). Despite significant improvements in
prevention and treatment in CAD it remains the leading cause of death worldwide
(Khera and Kathiresan, 2017). Several environmental factors contribute to the
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development of coronary artery disease, including hyperlipidemia, hypertension,
diabetes, and smoking (Malakar et al., 2019). Some Mendelian disorders have been
associated with CAD, including familial hypercholesterolemia, which led to the
development of novel therapies from the prevention of CAD (Malakar et al., 2019).
The most notable of these are hydroxymethylglutaryl-coenzyme A (HMG-CoA)
inhibitors, or statins, which inhibit the rate-limiting step in cholesterol biosynthesis
(Ward et al., 2019). Other single gene disorders associated with
hypercholesterolemia and CAD include mutations in the LDL receptor genes and in
proprotein convertase subtilisin/kexin type 9 (PCSK9), which sequester LDL
receptors for degradation thus reducing LDL cholesterol levels within the cell (Ogura,
2018; Malakar et al., 2019). These include mutations in low density lipoprotein
receptor, LDLR, apolipoprotein A-V, APOA5, and proprotein convertase
subtilisin/kexin type 9, PCSK9, which predispose to coronary artery disease
(Lehrman et al., 1985; Soria et al., 1989; Abifadel et al., 2003; Musunuru and
Kathiresan, 2019).
In response to statins, cells increase the number of low-density lipoprotein
receptors. One way the cell counteracts this increase in LDL receptors is through
overexpression of PCSK9 (Ogura, 2018). To combat this effect, PCSK9 inhibitors
have been developed to prevent the degradation of LDL receptors. In combination
with statins, PCSK9 inhibitors have been shown to lower LDL cholesterol and reduce
plaque burden (Ogura, 2018).
IV. ACTA2 and Multisystemic Smooth Muscle Dysfunction Syndrome
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Smooth muscle alpha actin (SMA), encoded by ACTA2, makes up 40% of the
total protein within SMCs and 70% of the total actin making it the most abundant
protein in SMCs (Guo et al., 2007). Mutations in ACTA2 are responsible for as much
as 21% of inherited thoracic aortic aneurysms and dissections and that some
ACTA2 mutations lead to a widespread vascular phenotype (Guo et al., 2009). Our
laboratory originally identified mutations in ACTA2 as pathogenic for TAAD.
Smooth muscle cells from patients with mutations in ACTA2 show multiple
abnormalities, including an absence of SMA filaments and large amounts of
unpolymerized SMA (Guo et al., 2007). In addition, aortic tissue from these patients
had increased proteoglycan content and fragmentation and loss of elastin fibers
(Guo et al., 2007). They also displayed an overall reduction in SMC content with
occasional areas of increased numbers of disorganized smooth muscle cells.
Interestingly, tissue from these patients had abnormal vasa vasorum with thickened
medial layers and partial or total occlusion of the vessel lumen by cells staining
positive for SMC (Guo et al., 2007).
Mutations in ACTA2 were originally thought to lead to aneurysmal disease
exclusively. The finding of medial thickening in the vasa vasorum along with the
observation that patients with mutations in ACTA2 all had livedo reticularis, a
purplish, network-pattern skin discoloration due to constriction or occlusion of deep
capillaries in the skin, suggested an occlusive component to the ACTA2 phenotype
(Guo et al., 2007). A study of twenty families, including a total of 127 family
members with known heterozygous ACTA2 mutations revealed striking evidence
that mutations in ACTA2 also lead to early onset vascular occlusive disease (Guo et
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al., 2009). For the purpose of these studies, early-onset vascular occlusive disease
is defined as disease onset before the age of 55 years in men and before the age of
60 years in women (Guo et al., 2009). As might be expected, TAAD was the primary
vascular pathology identified in this cohort (76 of the 127 mutation carriers), but
early-onset coronary artery disease (CAD; 26 carriers) and ischemic strokes (15
carriers) were also common findings (Guo et al., 2009). What makes these findings
more striking is that none of the family members without a mutation in ACTA2 were
affected by TAAD, early-onset CAD or stroke (Guo et al., 2009). Overall, these data
found that patients carrying a mutation in ACTA2 were significantly more likely to
have premature CAD or stroke than those who did not, drawing a clear link between
mutations in ACTA2 and vascular occlusive disease (Guo et al., 2009). Five
mutation carriers from families noted to have very early onset strokes (age less than
20 years) had been diagnosed with Moyamoya Disease (Guo et al., 2009).
IV. Majewsky Osteodysplastic Primordial Dwarfism Type II
Microcephalic Primordial Dwarfism (MPD) encompasses a group of disorders
characterized by severe pre- and post-natal growth restriction with microcephaly
(Bober and Jackson, 2017). Multiple forms of MPD have been identified in the
literature (Bober and Jackson, 2017). The most common of these is Majewsky
Osteodysplastic Primordial Dwarfism Type II (MOPDII) (Bober and Jackson, 2017).
Initially thought to overlap with Seckel Syndrome, which is due to mutations in the
ataxia-telangiectasia and Rad3-related (ATR) gene, a 2008 study of 25 unrelated
individuals with a clinical diagnosis of MOPDII identified PCNT as the underlying
mutation in these patients (Griffith et al., 2008; Rauch et al., 2008).
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Majewski Osteodysplastic Primordial Dwarfism Type II (MOPDII) is a rare
autosomal recessive disorder resulting from loss of function mutations in the gene
encoding pericentrin, PCNT (Rauch et al., 2008; Willems et al., 2009). Affected
individuals have severe growth restriction beginning in utero and persisting
postnatally with an average adult height of about 100 cm. Individuals with MOPDII
also have severe microcephaly that becomes progressively more disproportionate
as patients age (Hall et al., 2004; Bober et al., 2010). MOPDII is distinguishable from
other, similar forms of primordial dwarfism by the presence of characteristic bony
dysplasia and facial features, and by affected patients having normal or near-normal
intelligence (Hall et al., 2004; Willems et al., 2009; Bober et al., 2010).
Individuals with MOPDII have significant morbidity and mortality due to
diverse, early-onset vascular diseases, including cerebral aneurysms, Moyamoya
Disease (MMD) and coronary artery disease (CAD) (Hall et al., 2004; Brancati et al.,
2005; Chen et al., 2014a). The incidence of cerebrovascular disease in these
patients, including early onset, rapidly progressive MMD, multiple cerebral
aneurysms, and increased vessel tortuosity, has been found to be as high as 1952% in the published literature (Hall et al., 2004; Bober et al., 2010). Severe, early
onset multi-vessel coronary artery disease is another common cause of morbidity
and mortality in these patients (Bober et al., 2010). Other vascular findings in
patients with MOPDII include bicuspid aortic valve, atrial septal defect, patent ductus
arteriosus, myocarditis leading to myocardial infarct, renal artery aneurysms, and
pulmonary artery stenosis (Bober et al., 2010). The goal of this study is to elucidate
the etiology of the vascular pathology in these patients, which is currently unknown.
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MOPDII is associated with loss of function mutations in the gene encoding the
centrosome scaffold protein pericentrin, PCNT (Rauch et al., 2008). Through its
function in the centrosome, pericentrin is involved in a wide range of cellular
activities, including microtubule nucleation, mitotic spindle orientation, and cell cycle
regulation. Based on these roles, three main models have been proposed to explain
the etiology of the clinical manifestations in patients with MOPDII (Delaval and
Doxsey, 2010).
A. Mitotic Spindle Misorientation During Asymmetric Cell Division
During cell division, positioning of the mitotic spindle determines whether a
cell divides symmetrically, producing two identical daughter cells, or asymmetrically,
producing daughter cells destined for two different cell fates (Alberts et al., 2015).
During mitosis pericentrin is localized to the centrosome and acts as a molecular
scaffold for the recruitment of other proteins involved in centrosome maturation
(Chen et al., 2014). Knocking-out Pcnt in mice leads to misorientation of the mitotic
spindle, decreased symmetric cell division in neural progenitor cells, and increased
misoriented divisions in fibroblasts (Chen et al., 2014). Decreased symmetric cell
division in the neural progenitor pool is hypothesized to cause the microcephaly in
these patients (Delaval and Doxsey, 2010; Chen et al., 2014). It is unclear what
effect, if any, this would have on the smooth muscle cell population. Vascular
smooth muscle cells arise from multiple embryonic origins, but both the cerebral
vasculature and the ascending aorta arise via migration from neural crest cell
progenitors (Majesky, 2007). A role for asymmetric cell division in smooth muscle
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cell differentiation has not been defined. Therefore, this hypothesis will not be
pursued in my studies.
B. Microtubule Nucleation Defects
Microtubules (MTs) make up the cell cytoskeleton and are involved in cell
growth, movement, and adhesion in addition to determining organelle positioning
and cell polarity (Alberts et al., 2015). Pericentrin plays a key role in anchoring the γTubulin Ring Complex (γ-TuRC) for centrosome MT nucleation (Takahashi et al.,
2002; Zimmerman et al., 2004; Rauch et al., 2008; Alberts et al., 2015). Radial MTs
originating from the centrosome maintain cellular circularity, while MTs originating
from sites outside the centrosome, such as the Golgi, provide for directional growth
(O’Rourke et al., 2014). During interphase, pericentrin and another centrosome
scaffold protein, Cep192, interact in an antagonistic manner to regulate centrosome
MT nucleation, with depletion of pericentrin leading to increased centrosome MT
nucleation. This increase in centrosome MT nucleation may in turn off-set the
balance between radial and directional MT nucleation affecting cell migration
(O’Rourke et al., 2014). Vascular smooth muscle cells (SMCs) migrate from the
medial layer of the vessel wall into the intima in response to injury (Milewicz et al.,
2010; Papke et al., 2013). Therefore, it is possible that loss of pericentrin may in turn
lead to defects in SMC migration in response to vessel injury. However, this would
likely only play an indirect role in development of vascular occlusive disease;
therefore, my studies will focus on cell proliferation and loss of ATR-dependent
checkpoint regulation described below.
C. Loss of ATR-Dependent Checkpoint Regulation
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Pericentrin has also been found to play a direct role in the regulation of the
G2/M checkpoint (Griffith et al., 2008; Delaval and Doxsey, 2010). Checkpoint
kinase 1 (Chk1), part of the ataxia telangiectasia and rad3 related (ATR)-dependent
DNA damage checkpoint signaling pathway (Figure 1), is anchored to the
centrosome by pericentrin (Griffith et al., 2008; Tibelius et al., 2009). Once at the
centrosome, Chk1 inhibits G2/M cell cycle progression through deactivation of
Cdc25B (Schmitt et al., 2007; Tibelius et al., 2009). In turn, siRNA knock-down of
pericentrin in U2OS cells was shown to lead to an increase in the number of cells in
late G2 or mitosis (Tibelius et al., 2009). Specifically, in smooth muscle cells, work
by Ye and colleagues shows that the Polymerase I inhibitor, CX-5461, decreases
neointimal formation via activation of the ATR pathway in SMCs. However, when the
ATR pathway is simultaneously inhibited using the ATR inhibitor VE-821, the
inhibitory effect of CX-5461 on neointimal formation is abolished (Ye et al., 2017).
Interestingly, the primary form of Seckel Syndrome (SCKL1, OMIM #210600), a
closely related form of primordial dwarfism often confused with MOPDII, is caused
by mutations in ATR. SCKL1 is also associated with vascular pathology including
intracranial aneurysms, MMD, and malignant hypertension, although at a lower rate
than MOPDII (Galasso et al., 2008; Rahme et al., 2010). These findings suggest that
the ATR checkpoint is critically important in regulating smooth muscle cell
proliferation and disruption of the ATR pathway via loss of pericentrin may result in
aberrant cell proliferation.
Vascular Smooth Muscle Cells
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Vascular smooth muscle cells (SMCs) are the main mesenchymal cell type
making up the artery wall. Located in the medial layer of the artery wall, smooth
muscle cells are organized into lamellar units with SMCs oriented longitudinally
between layers of elastin, surrounded by ECM, where they function to regulate blood
pressure while also producing extracellular matrix (El-Hamamsy and Yacoub, 2009).
SMCs originate from diverse embryonic origins (figure 1.2). So far eight
different embryonic origins have been identified, including the neural crest,
proepicardium, somites, and splanchnic mesoderm, among others (Majesky, 2007,
2018). The ascending aorta, aortic arch, and bilateral common carotid arteries all
arise from progenitor cells of the neural crest lineage (Majesky, 2007). While the
coronary arteries, instead of growing out from the aorta, develop separately from
proepicardium progenitors (Majesky, 2007). The boundaries between these
embryonic origins are sharply demarcated, although, regardless of origin, SMCs all
express the same constellation of differentiation markers, including smooth muscle
alpha-actin (SMA, encoded by ACTA2), smooth muscle myosin heavy chain
(SMMHC, encoded by MYH11), calponin (encoded by CNN1), and Transgelin
(SM22α, encoded by TAGLN) (Majesky, 2007).
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Figure 1.2. Embryonic origins of vascular
SMCs in the aorta. From Majesky et al, 2007.
Unlike cardiac myocytes and skeletal muscle, vascular smooth muscle cells
are not terminally differentiated and have the unique ability to de-differentiate in
response to environmental stimuli (El-Hamamsy and Yacoub, 2009). As mentioned
previously, differentiated SMCs express various contractile proteins. In cell culture,
SMCs can downregulate these SMC markers and display increased migration,
proliferation, and extracellular matrix deposition, so called de-differentiation. SMC
differentiation is regulated by the transcription factor serum response factor (SRF)
and its cofactor myocardin (Owens et al., 2004; Wang et al., 2018). As the name
suggests, myocardin is only expressed in cardiomyocytes and SMCs (Wang et al.,
2018). A variety of pathways lead to SRF-myocardin complex formation responding
to signals for either proliferation or contractility (Frismantiene et al., 2018; Wang et
al., 2018). Once formed, this complex binds to CArG box, which in turn controls
expression of SMC-specific genes as well as several immediate-early genes (Wang
et al., 2018).
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Figure 1.3. Phenotypic switching of vascular smooth muscle
cells. SMCs are not terminally differentiated and have the ability
to switch between a differentiated, non-proliferative contractile
phenotype and a de-differentiated, proliferative synthetic
phenotype. [Used with permission from Milewicz et al, Genetics
in Medicine, 2010.]
Signaling Pathways Regulating SMC Differentiation
One pathway by which SRF-myocardin may be activated is the TGF-β
pathway (Frismantiene et al., 2018). Release of TGF-β is controlled by contraction
and relaxation of the ECM (Frismantiene et al., 2018; Michel et al., 2018; Wang et
al., 2018). In addition, it is also released during proteolytic activity such as that
involving plasmin and matrix metalloproteinases (MMPs). TGF-β induces SMC
differentiation through SRF-myocardin. When released, TGF-β acts to regulate SMC
interaction with the ECM by increasing the number of focal adhesions on the cell
surface through which the cytoskeleton interacts with the ECM (Majesky, 2016;
Frismantiene et al., 2018; Wang et al., 2018). Through this feedback interaction on
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SMCs, TGF- β serves to regulate the ECM composition (Frismantiene et al., 2018;
Michel et al., 2018; Wang et al., 2018).
In addition to myocardin, SRF also interacts with myocardin-related
transcription factor (MRTF) (Papke et al., 2013). Unlike myocardin, MRTF shuttles
between the cell cytoplasm and the nucleus (Papke et al., 2013). In the cytoplasm,
MRTF binds to monomeric actin (Papke et al., 2013). As actin filaments polymerize,
MRTF is released revealing a nuclear localization sequence (Papke et al., 2013). In
the nucleus, MRTF binds to SRF activating transcription of SMC contractile genes
(Papke et al., 2013). When MRTF releases from SRF it is sequestered back to the
cytoplasm where it binds to monomeric actin (Papke et al., 2013). Once unbound to
MRTF, SRF is free to bind other factors activating SRF-regulated growth responsive
genes leading to increased proliferation of SMCs in response to proliferative signals
and growth factors (Papke et al., 2013).
The most prominent growth factor influencing SMC proliferation and migration
is platelet derived growth factor (PDGF) (Papke et al., 2013). The PDGF family
includes four polypeptide chains which combine into five dimeric forms, PDGF-AA,
PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD (Wang et al., 2018). Of these five,
PDGF-BB is the most potent SMC mitogen (Wang et al., 2018). In response to
PDGF-BB, SMC migrate to the vessel intima where synthetic SMC may promote
pathologic neointimal formation and narrowing of the vessel lumen through excess
ECM deposition (Frismantiene et al., 2018).
Atherosclerosis
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Atherosclerotic vascular disease is an underlying cause of diverse vascular
disease, including heart attack and stroke, making it a contributing factor to the
leading cause of death worldwide (Herrington et al., 2016). Atherosclerosis is due to
retention of apolipoprotein B-containing lipoproteins in the subendothelial space of
the artery wall (Tabas et al., 2015). Lipoproteins are composed of lipid and protein,
including low-density lipoproteins (LDL) and high-density lipoproteins (HDL)
(Ahotupa, 2017). Lesions develop in specific lesion-prone areas of the artery wall
with low or oscillatory endothelial shear stress which contribute to endothelial
dysfunction and a susceptibility to lipoprotein retention, this in turn stimulates the
entry and differentiation of monocytes into macrophages (Bentzon et al., 2014;
Tabas et al., 2015).
In the pre-atherosclerotic stage, termed diffuse intimal thickening, SMCs
undergo de-differentiate and migrate from the medial layer to the intimal layer where
they produce proteoglycans and elastin, without any lipid deposition (Dubland and
Francis, 2016). As the plaque progresses, it accumulates acellular, lipid-rich material
with an overlying layer of SMCs and lipid-laden macrophages, termed pathologic
intimal thickening (Nakashima et al., 2007; Bentzon et al., 2014). One hypothesis for
early atherogenesis is the response-to-retention hypothesis, which posits that
“atherogenic lipoproteins are retained in the intima by binding to extracellular
proteoglycans” (Williams and Tabas, 1995; Nakashima et al., 2007). These
lipoprotein-proteoglycan complexes in turn increase oxidation and lead to uptake by
macrophages to form foam cells (Demyanenko and Uzdensky, 2017).
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As the plaque progresses macrophages and SMCs invade the lipid-rich core
and undergo apoptosis leading to necrotic core development (Bentzon et al., 2014).
At this point the lesion is termed a fibroatheroma (Bentzon et al., 2014). New vessels
may then grow into the plaque from the vaso vasorum allowing entry of addition
monocytes and other immune cells (Bentzon et al., 2014). These new vessels are
fragile and leaky, prone to bleeding leading to additional inflammation within the
plaque (Bentzon et al., 2014). De-differentiated, synthetic SMCs lie down a matrix of
collagen, elastin, and proteoglycan (Bentzon et al., 2014). In addition, calcifications
may develop in the plaque forming a fibrocalcific plaque (Bentzon et al., 2014).
The most common cause of thrombosis leading to blockage of a coronary
artery and myocardial infarction is plaque rupture (Bentzon et al., 2014). Plaque
rupture occurs when there is a defect in a thin fibrous cap allowing the thrombogenic
plaque core to come into contact with blood (Bentzon et al., 2014). This thinning is
most likely due to loss of synthetic SMCs leading to a reduction in collagen in
conjunction with breakdown of the existing collagen matrix by macrophages
(Bentzon et al., 2014; Bennett et al., 2016). SMCs from advanced plaques undergo
less proliferation with an increased percentage of cells in G1, indicating growth
arrest (Bennett et al., 2016). This suggests that SMC proliferation may be protective
by reinforcing the fibrous cap (Bennett et al., 2016).
Phenotypic Modulation in SMCs
In addition to SMC’s ability to de-differentiate, they also have the ability to
undergo a process termed phenotypic modulation in which SMCs take on a
macrophage-, fibroblast-, or mesenchymal stem cell (MSC)-like phenotype (Bennett
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et al., 2016; Alencar et al., 2020). Complications such as heart attack and stroke
arise when an unstable atherosclerotic plaque ruptures (Shankman et al., 2015;
Bennett et al., 2016). Plaque stability is at least in part a function of its cellular
composition with a thick fibrous cap comprised of SMA-positive SMCs conferring
stability (Bennett et al., 2016). Conversely, a thin cap with few SMA-positive cells,
large numbers of cells expressing macrophage markers such as CD68 and LGALS3,
and a large necrotic core containing lipid-laden foam cells denote plaque instability
(Shankman et al., 2015; Bennett et al., 2016).

Figure 1.4. Current knowledge of identity and origins of vascular
smooth muscle cells. SMCs can also undergo phenotypic
modulation to multiple cellular phenotypes, including
macrophage-, fibroblast-, and mesenchymal stem cell-like cell
populations. This phenotypic modulation is thought to be
mediated through the transcription factor Klf4. [From Bennett et
al, 2016.]
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In the presence of cholesterol, SMCs can undergo a process termed
phenotypic modulation, downregulating contractile markers and upregulating
markers of macrophages, fibroblasts, and MSCs (Shankman et al., 2015; Wirka et
al., 2019; Chattopadhyay et al., 2020). As much as 20-30% of CD68-positive cells
within advanced atherosclerotic plaques are of SMCs origin (Shankman et al., 2015;
Bennett et al., 2016). These macrophage-like cells differ from traditional
macrophages in that they have a reduced phagocytic capacity, which is thought to
contribute to a pro-atherosclerotic phenotype by a reduced ability to clear dying
cells, lipids, and debris, and by exacerbating inflammation (Bennett et al., 2016).
This downregulation of contractile markers in phenotypically modulated SMCs
has been shown to be mediated through the transcription factor KLF4 (Shankman et
al., 2015). SMC-specific conditional knockout of Klf4 resulted in a reduction in lesion
size, an increase in lesion stability, and a reduction in SMC-derived MSCs and
macrophages (Shankman et al., 2015). These findings suggest that while synthetic
SMCs appear to stabilize the fibrous cap, phenotypically modulated SMCs lead to
plaque destabilization.
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Chapter 2: Liver and lung pathology in patients with Multisystemic Smooth Muscle
Dysfunction Syndrome due to ACTA2 pathogenic variants disrupting R179
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Introduction
Heterozygous pathogenic variants in ACTA2, encoding smooth muscle αactin (SMA), ACTA2, are responsible for 15% of familial thoracic aortic aneurysms
and dissections (Morisaki et al., 2009; Regalado et al., 2015). De novo, missense
mutations disrupting arginine 179 (ACTA2 p.Arg179) lead to severe disease termed
Smooth Muscle Dysfunction Syndrome (SMDS) that is characterized by patent
ductus arteriosus (PDA) or aortopulmonary window (APW), childhood onset of
thoracic aortic aneurysms and dissections and moyamoya-like cerebrovascular
disease, primary pulmonary arterial hypertension, congenital mydriasis, intestinal
hypoperistalsis and malrotation, and hypotonic bladder (SMDS, MIM# 613834)
(Milewicz et al., 2010b; Brodsky et al., 2014; Logeswaran et al., 2017; Regalado et
al., 2018; Taubenslag et al., 2019).
The clinical complications of SMDS and treatment guidelines have been
delineated (PMID: 33199432, Regalado et al., 2018). Early deaths in these patients
are due to aortic complications, strokes due to the cerebrovascular disease, and
pulmonary complications. Pulmonary disease in patients with SMDS include chronic
lung disease and asthma (27%), requirement for respiratory tract agents and/or
home oxygen in one-third of patients, and pulmonary arterial hypertension in half of
the patients (Regalado et al., 2018). In addition, persistent dilation of the main
pulmonary artery and/or its branches, a finding often associated with pulmonary
arterial hypertension, is present in half of SMDS patients (Raymond et al., 2014;
Regalado et al., 2018). One-third of affected individuals die prematurely of
pulmonary complications. Lung histology from one SMDS patient revealed
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emphysematous changes in the lung, along with thickening of the arterial walls
consistent with pulmonary hypertension (Prabhu et al., 2017). Hepatic complications
also occur in SMDS patients, including one infant who died of acute fulminant liver
failure, and another who had transiently elevated hepatic transaminases of unknown
etiology (Munot et al., 2012).
Aortic and cerebrovascular pathology in patients with mutations in ACTA2
R179 have been described previously, but limited data are available on the
pulmonary and hepatic pathology. Presented here are clinical and histologic findings
at autopsy of three unrelated patients with SMDS. The data highlight previously
undescribed liver and lung structural abnormalities in these patients.
Materials and Methods
The study protocol was approved by the Institutional Review Board of the
University of Texas Health Science Center at Houston and the patient or family
members consented to these studies. Pathology slides of the liver and lung were
obtained at autopsy from three patients with SMDS. Control tissue was obtained
from a 5.5-month-old female who died due to a post-operative sickle cell crisis and a
46-year-old male who died of complications of glioblastoma multiforme. Medical
records, including imaging reports, surgical reports, pathology reports, and
physicians’ notes, were reviewed.
Liver and lung sections from each patient were stained with hematoxylin and
eosin (H&E). Wall thickness was calculated using ImageJ software. The outer area,
including the media and intima, was measured and the luminal area subtracted.
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Percent wall thickness was then calculated by dividing the wall area by the total
outer area and calculating the percentage.
Results
Clinical data
Patient 1 is a 6-month-old infant boy with SMDS who inherited the ACTA2
p.Arg179His mutation from his mother, a 26-year-old with SMDS. The mother had
surgical repair of a PDA in infancy and surgical repair of the aortic valve, root,
ascending aorta, and an inferior hemiarch for an aortic coarctation at 24 years of
age. Fetal echocardiography 5 weeks prior to delivery revealed normal heart size
with mild dilation of the main pulmonary artery. The proband was delivered at 37 6/7
weeks via uncomplicated, planned cesarean section. APGARs were 4/4/9 at 1/5/10
minutes, respectively, and the neonate was subsequently transferred to the neonatal
intensive care unit for respiratory distress where he required positive pressure
ventilation, CPAP and supplemental oxygen. The infant went on to have a
complicated course due to his large PDA, pulmonary hypertension, biventricular
cardiac hypertrophy, intestinal malrotation requiring surgical intervention, and
megacystis. The infant ultimately succumbed to respiratory failure. At autopsy, gross
examination revealed an enlarged urinary bladder with an abnormally thick wall,
normal liver, firm and darkly discolored lungs, and an enlarged heart. The ductus
arteriosus was fully patent and approximately the same diameter as the aorta
pulmonary trunk.
Patient 2 is a baby girl with a de novo ACTA2 p.Arg179His mutation who had
a complicated neonatal course that included surgical repair of a PDA and APW,
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persistent pulmonary hypertension of the newborn that resolved 10 days after PDA
surgery, and seizures and suspected moyamoya disease. She was subsequently
diagnosed with congenital mydriasis, nephrolithiasis, and gastroesophageal reflux
disorder. Genetic testing revealed the ACTA2 variant. At 22 months of age, she was
admitted for acutely increased work of breathing in the setting of a possible viral
illness. She died on hospital day 12 of her admission following attempted intubation
for persistent tachypnea, increased work of breathing and carbon dioxide retention
despite the use of Bilevel Positive Airway Pressure (BiPap).
On autopsy, gross examination revealed a flaccid-appearing urinary bladder
with a thin wall. The pulmonary trunk was slightly enlarged and there was a small
aneurysm on the posterior aspect of the proximal aorta. There was hyperinflation of
the lung apices bilaterally with a wedge-shaped hemorrhagic area in the upper lobe
of the right lung. The middle and lower lobes of the right lung were edematous with
dark purple parenchyma and a firm, boggy consistency. The left lung was partially
collapsed with the remainder of the lung pink and edematous with patchy firm areas.
The lung parenchyma had multiple areas of microcystic architecture and extensive
bronchiectasis. The liver was normal in appearance.
Patient 3 is a 32-year-old female with a de novo ACTA2 p.Arg179His
mutation. Her past medical history, hospital course, and cerebrovascular pathology
have been described previously (Georgescu et al., 2015). Briefly, she had a medical
history of surgical repair of a PDA and thoracoabdominal aortic aneurysm,
congenital absence of the iris, congenital intestinal malrotation, postural orthostatic

27

tachycardia, asthma, and dysrhythmia. She died secondary to large bilateral anterior
cerebral artery and left middle cerebral artery infarcts resulting in herniation.
SMDS Associated Liver Pathology
Liver sections from the SMDS patients showed abnormalities in the portal
triad not present in the livers of age matched controls who died of other causes. All
three SMDS patients had expansion of the portal tracts with increased connective
tissue deposition (Figure 2.1a, c, asterisks). In addition, the terminal branches of
the hepatic artery in all three SMDS patients showed marked medial thickening in
the affected patients when compared to controls (Figure 2.1a, arrows). The
quantification of the thickness of the terminal branches of the hepatic artery in the
SMDS patients’ liver sections showed significant increase in the wall thickness when
compared with control livers (Figure 2.1b, d).
All three patients were also noted to have additional abnormalities in the liver
parenchyma suggestive of an overall poor metabolic state, including non-alcoholic
hepatic steatosis in all three patients. The six-month old was noted to have
intrasinusoidal nucleated erythrocytes, suggesting chronic hypoxia, likely secondary
to this infant’s longstanding severe pulmonary hypertension and resulting respiratory
failure (Vazquez et al., 2015). Note, the infant control had sickle cell anemia also has
intrasinusoidal nucleated erythrocytes potentially secondary to bone marrow
necrosis (Figure 2.1e, f).
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Figure 2.1. Thickening of the terminal branches of the hepatic artery,
expansion of the portal tracts, and non-alcoholic hepatic steatosis in 6- and
22-month-old infants and a 32-year-old adult with SMDS. Hematoxylin and
eosin staining of liver sections from all three patients with SMDS show
thickening of the terminal branches of the hepatic artery compared to
controls (a, c, white arrow). Quantification of the vessel wall thickness
(percent) shows a significant increase in the artery wall thickness in both the
6 month (p=0.0004) and 22 month (p≤0.0001) old infants (b) and the 32 year
(p≤0.0001) old adult (d) patients compared to the infant and adult control,
respectively. Expansion of the portal tracts due to extracellular matrix
deposition is also apparent in the SMDS patient tissue compared to the
control (a, c, asterisks). The remainder of the portal triad, the portal vein (a,
c, green arrow) and bile duct (a, c, black arrow), are normal in appearance.
Finally, imaging of the liver parenchyma shows evidence of non-alcoholic
hepatic steatosis in all three SMDS patients (e).
Lung Pathology in SMDS
All three patients had emphysematous changes and the two infant patients had
evidence of pulmonary hypertension, similar to a previously reported patient with
SMDS (Figure 2.2) (Milewicz et al., 2010b). The 6-month-old patient, who did not
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undergo repair of his PDA, had advanced grade 2-3 pulmonary hypertension, with
concentric, fibrocellular medial and intimal thickening of the pulmonary arterioles and
small arteries with severe congestion (Figure 2.2e, black arrowhead). The 22month-old patient, whose APW was repaired, had grade 1, pulmonary hypertension
with hypertrophy of the media alone (Figure 2.2e, white arrowhead). Patient 3 did
not have significant pulmonary arterial changes.
The alveolar spaces were significantly enlarged in all three patients, with the
31-year-old patient displaying the most severe emphysematous changes, including
prominent interalveolar connections, pores of Kohn (Figure 2.2d, black
arrowheads). Additionally, all three patients had significant thickening of the
alveolar septae with congestion of the alveolar capillaries, most significantly in
patient 1 (Figure 2.2e, f, black arrows).
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Figure 2.2. All three SMDS patients exhibit severe lung changes consistent with
pulmonary hypertension and emphysematous changes. Hematoxylin and eosin
staining demonstrated significant arterial wall thickening consistent with severe
pulmonary hypertension. The 6-month old patient demonstrates advanced grade
2-3 pulmonary hypertension, with concentric, fibrocellular medial and intimal
thickening of the pulmonary arterioles and small arteries with severe congestion
(e, black arrowhead). The 22-month-old patient, whose APW was repaired,
appeared to have less severe, grade 1, pulmonary hypertension with
hypertrophy of the media alone (e, white arrowhead). In addition, all three
patients had significant thickening of the alveolar septae with congestion of the
alveolar capillaries (e, f, black arrows). Finally, alveolar spaces are significantly
enlarged in all three patients with the 31-year-old patient displaying the most
severe emphysematous changes, including prominent pores of Kohn (d, black
arrowheads).
Discussion
We describe here pulmonary and hepatic pathology observed at autopsy in
three patients with SMDS. The lung parenchyma of all three patients showed
emphysematous changes, as was described in two previous patients (Regalado et
al., 2018). Chronic lung disease and asthma requiring medication and even
supplemental oxygen are frequent findings in patients with SMDS (Regalado et al.,
2018). Hyperinflation of the upper lung segment and cystic lung disease have also
been described in two patients (Milewicz et al., 2010b). The more detailed findings
reported here, especially the emphysematous changes in the 6-month-old, suggest
that SMDS causes selective defects in lung development.
Smooth muscle α-actin is expressed in both airway and vascular smooth
muscle cells in the developing lung (Moiseenko et al., 2017). The lung develops in
multiple stages starting with the embryonic stage, followed by the pseudoglandular,
canalicular, saccular and finally the alveolar stage (Mullassery and Smith, 2015).
Smooth muscle cell localization and regulation is crucial for the proper development
of the lung (Danopoulos et al., 2018). Segmental branching of the airway occurs
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early during the embryonic stage of lung development. Smooth muscle α-actin
expressing cells play a central role in driving branching morphogenesis (Danopoulos
et al., 2018; Goodwin et al., 2019). Disruption of smooth muscle cells during
branching prevents terminal bifurcation during lung development interfering with
alveolar formation (Kim et al., 2015). Studies in rodent models show that ASMAexpressing lung myofibroblasts participate in alveolar maturation, presumably
guiding active septation (Dickie et al., 2007). In the normal lung, the pores of Kohn in
the alveolar walls are small, but as the wall breaks down in destructive emphysema,
the pores of Kohn enlarge and increase in number (Yoshikawa et al., 2016). This
increase in the pores of Kohn, such as seen in these patients with SMDS, leads to a
reduction in the area for gas exchange and a decrease in both the capillary bed and
elastic recoil affecting pulmonary function (Yoshikawa et al., 2016). Taken together,
alterations in SMA expressing lung smooth muscle cells and myofibroblasts caused
by SMDS appears to impair alveolar development and enables airspace
deterioration.
All three patients presented here had arterial changes consistent with
pulmonary hypertension, an established complication of SMDS (Milewicz et al.,
2010b; Regalado et al., 2018). SMDS also predisposes to moyamoya disease and
pathologic changes of medial thickening and diffuse neointimal changes in the
cerebrovascular arteries (Georgescu et al., 2015). Combined with our demonstration
of arterial thickening in the liver outlined here, these findings suggest that SMDS
leads to diffuse SMC arterial thickening. Fetal echocardiography of Patient 1 at 32
6/7 weeks found normal heart systolic function but mild dilatation of the main
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pulmonary artery and ascending aorta, suggesting that pulmonary arterial changes
are developmental in origin, independent of blood flow. Overall these observations
suggest that the pulmonary arterial changes in patients with SMDS align with the
pathology found in other muscular arteries in SMDS patients (Milewicz et al., 2010b;
Munot et al., 2012; Georgescu et al., 2015).
Expansion of the portal tracts with increased connective tissue, medial
thickening of the terminal branches of the hepatic artery, and non-alcoholic hepatic
steatosis were noted in all three SMDS patients. Hepatic steatosis, an excessive
accumulation of triglycerides within hepatocytes, has a wide range of etiologies,
including alcoholic liver disease, drugs, disordered metabolism, and infections
(Idilman et al., 2016). Given the health status of the three patients described here,
metabolic causes of steatosis are plausible in these patients. One reason for why
some patients with SMDS may go on to develop elevated liver enzymes and even
fulminant liver failure is suggested by Graaff et al, 2018. They posit that relative
hepatic hypoxia predisposes to progression of non-alcoholic fatty liver disease (van
der Graaff et al., 2019). It is possible that the pulmonary pathology in conjunction
with the significant thickening of the terminal branches of the hepatic artery in these
SMDS patients may predispose these individuals to hepatic hypoxia and progressive
liver disease. Hypoxia in turn can activate the resident hepatic macrophages,
Kupffer cells (van der Graaff et al., 2019). Therefore, elevated transaminases and
progression to fulminant liver failure in patients with SMDS may arise due to relative
hypoxia leading to an inflammatory response by Kupffer cells, which in turn activate
hepatic stellate cells (HSCs) through the secretion of TGF-β1. Hepatic stellate cells
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express high levels of SMA (Khomich et al., 2019). Hepatic steatosis alone can
trigger HSC activation in the absence of other inflammatory processes due to
increased TGF-β production by hepatocytes (Khomich et al., 2019). SMA in HSCs
plays a critical role in contraction and cytoskeletal structure without significantly
influencing proliferation or migration (Rockey et al., 2019). After carbon tetrachloride
induced liver injury, Acta2-/- mice expressed significantly fewer HSCs compared to
Acta2+/+ mice with a corresponding reduction in collagen (Rockey et al., 2019).
These findings suggest that SMA expression by HSCs plays a key role in liver
wound healing and hepatic fibrosis (Rockey et al., 2019). By this view, mutations in
ACTA2, such as the R179H mutation, would compromise hepatic repair and
regeneration in response to injury.
In conclusion, patients with SMDS have a widespread arteriopathy, including
narrowing of the intracranial arteries, aortic aneurysms and dissections, thickening of
the terminal branches of the hepatic artery, and thickening of the pulmonary
vasculature with pulmonary hypertension. Pathologically this arteriopathy is
characterized by medial thickening. We recommend that patients with SMDS be
monitored for liver disease and consider minimizing exposure to alcohol and
medications metabolized in the liver. In addition, patients with SMDS should also be
monitored closely for pulmonary complications and avoid risk factors that may
augment the pulmonary disease.
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Chapter Three: Smooth muscle cell specific knock-out of Pcnt leads to phenotypic
modulation in vitro and atherosclerosis in vivo
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Introduction
Majewski (or Microcephalic) Osteodysplastic Primordial Dwarfism Type II
(MOPDII) is a rare autosomal recessive disorder due to biallelic loss of function
mutations in the gene encoding the centrosome protein pericentrin, PCNT (Bober
and Jackson, 2017). MOPDII is the most common form of microcephalic primordial
dwarfism (Bober and Jackson, 2017). Patients with MOPDII have a very distinct
clinical phenotype, including proportionate pre- and post-natal growth restriction with
microcephaly, normal to near-normal intelligence, characteristic facial features, and
bone dysplasia (Hall et al., 2004).
Unlike other forms of primordial dwarfism, vascular pathology is a leading
cause of morbidity and mortality in these patients (Galasso et al., 2008; Bober and
Jackson, 2017). Up to half of patients with MOPDII develop cerebrovascular
pathology, including Moyamoya Disease and/or cerebral aneurysms (Bober et al.,
2010). These patients also develop other diverse vascular pathology, including
early-onset coronary artery disease, bicuspid aortic valve, atrial septal defect, patent
ductus arteriosus, renal artery stenosis, and pulmonary artery stenosis (Bober and
Jackson, 2017). With this in mind our laboratory created a smooth muscle cell
specific Pcnt knock-out mouse to better understand the pathogenesis of the vascular
phenotype in MOPDII. We can apply what we learn from rare conditions like
MOPDII, which have a disproportionate incidence of early onset vascular disease, to
better understand and treat more common forms of vascular disease as well.
Pericentrin
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Pericentrin is a large coiled-coil protein, 380 kDa in humans and 360 kDa in
mice, located on chromosome 21 in humans and chromosome 10 in mice (Mühlhans
and Gießl, 2012). Pericentrin is a scaffold protein for the pericentriolar material, the
collection of proteins making up the centrosome which is the main microtubule
organizing center of the cell (Zimmerman et al., 2004). Through its role as a
centrosome scaffold protein, pericentrin is involved in multiple cell functions,
including microtubule nucleation, mitotic spindle orientation, and cell cycle regulation
(Delaval and Doxsey, 2010).
During cell division the positioning of the mitotic spindle determines if a cell
divides symmetrically into two identical daughter cells or asymmetrically into two
daughter cells destined for different cell fates (Alberts et al., 2015). In the absence of
pericentrin, neural progenitor cells undergo symmetric cell division at a lower than
normal rate potentially leading to the microcephaly seen in patients with MOPDII
(Delaval and Doxsey, 2010; Chen et al., 2014a). Pericentrin plays a pivotal role in
centrosome microtubule nucleation by anchoring the γ-Tubulin Ring Complex
(Zimmerman et al., 2004; Alberts et al., 2015). Microtubules may originate either
from the centrosome, radial microtubules, or from sites outside the centrosome such
as the Golgi, directional microtubules (O’Rourke et al., 2014). Pericentrin works in an
antagonistic manner with another protein, Cep192, to regulate microtubule
nucleation (O’Rourke et al., 2014). Depletion of pericentrin offsets this balance
leading to an increase in centrosome microtubule nucleation and may affect cell
migration (O’Rourke et al., 2014). Finally, pericentrin has been shown to play a
direct role in cell cycle regulation through the ataxia telangiectasia and rad3 related
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(ATR) pathway where it anchors checkpoint kinase 1 (Chk1) to the centrosome
(figure 3.1) (Griffith et al., 2008; Tibelius et al., 2009; Delaval and Doxsey, 2010).
When localized to the centrosome, Chk1 inhibits G2/M cell cycle progression
through inactivation of Cdc25B (Schmitt et al., 2007; Tibelius et al., 2009). In turn,
knock down of pericentrin in U2OS cells has been shown to lead to an increase in
cells in late G2 and mitosis (Tibelius et al., 2009).

Figure 3.1. Role of pericentrin in the ATR-Chk1 pathway. Various stimuli,
including mechanical stress, hypoxia, and oxidative stress, activate ATR
leading to the phosphorylation of Chk1. p-Chk1 is then recruited to the
centrosome by microcephalin (MCPH1) and pericentrin (PCNT). Once at the
centrosome, p-Chk1 phosphorylates Cdc25B, deactivating it. This in turn
leads to a reduction in Cdc25B-mediated dephosphorylation of pCdk1/CyclinB and inhibition of G2/M cell cycle progression.
Vascular Smooth Muscle Cells in Atherosclerosis
Vascular smooth muscle cells are the main cell type making up the artery
wall, localized to the medial layer where they contract to regulate blood pressure and
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produce extracellular matrix (El-Hamamsy and Yacoub, 2009). Differentiated smooth
muscle cells express an array of contractile proteins, including α-smooth muscle
actin (SMA), smooth muscle myosin heavy chain (SMMHC), calponin, and smooth
muscle 22α (SM22α) (Frismantiene et al., 2018). Unlike other muscle cells, vascular
smooth muscle cells have the ability to de-differentiate in response to certain
environmental stimuli, from a non-proliferative and non-migratory contractile
phenotype to a proliferative and migratory synthetic phenotype
(Owens et al., 2004; El-Hamamsy and Yacoub, 2009). In the pre-atherosclerotic
stage, vascular smooth muscle cells migrate from the medial layer of the cell to the
intimal layer where they produce proteoglycans and elastin leading to diffuse intimal
thickening (Dubland and Francis, 2016). In the early stages of atherosclerotic
disease development, extracellular LDL deposits form a fatty streak in the deep
intimal layer (Dubland and Francis, 2016). Once within the intimal layer SMCs dedifferentiate from a contractile phenotype to a proliferative, synthetic phenotype
(Dubland and Francis, 2016). Thickness of the fibrous cap overlying atherosclerotic
plaques is associated with plaque stability with a thin cap and a high ratio of
macrophages to SMCs being associated with an unstable plaque (Shankman et al.,
2015).
Foam cells were originally thought to be derived exclusively from
macrophages containing intracellular lipid droplets (Rong et al., 2003). Studies have
shown that loading of SMCs with cholesterol can induce the downregulation of
contractile markers, including SMA, α-tropomyosin, SMMHC, and calponin H1, and
upregulation of macrophage markers, including CD-68 and Mac-2 (Rong et al.,
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2003). This change was found to occur rapidly, within 48 to 72 hours (Rong et al.,
2003). Rong et al suggests that this process is a transdifferentiation process, rather
than de-differentiation. Lineage tracing experiments labeling SMCs have further
shown that as much as 82% of SMCs within atherosclerotic lesions are ACTA2
negative on immunostaining and transdifferentiated, or phenotypically modulated,
SMCs comprised as much as 30% of macrophage-like cells within atherosclerotic
lesions (Shankman et al., 2015). The downregulation of smooth muscle cell markers
in phenotypically modulated SMCs was further shown to be due to suppression by
Kruppel-like Factor 4 (KLF4) (Shankman et al., 2015). Recently, using single cell
RNA-Sequencing (scRNA-Seq), Wirka et al identified a distinct subset of
phenotypically modulated SMCs that appear and increase with disease progression
in atherosclerotic plaques in Apoe-/- (apolipoprotein E) mice fed a high fat diet (HFD)
(Wirka et al., 2019). These modulated SMCs (mSMCs) reduce expression of
contractile markers and upregulate expression of markers of macrophage,
fibroblasts (like Spp1 and Fn1) and stem cells (Sca1).
Several intracellular and extracellular factors can induce endoplasmic
reticulum (ER) stress and a consequent unfolded protein response (UPR). The UPR
becomes activated when the folding capacity of the ER is overwhelmed by the
accumulation of unfolded or misfolded proteins, in addition to the increased
expression of normal proteins, nutrient deprivation, alterations in calcium
homeostasis, or oxidative stress (Chattopadhyay et al., 2020). Inflammatory and
vascular cells within atherosclerotic lesions have been shown to have chronic ER
stress leading to activation of the UPR (Zhou et al., 2015). Stimulation of the UPR
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leads to the activation of three pathways: the protein kinase RNA-like ER kinase
(PERK) pathway, the inositol-requiring enzyme-1 (IRE1a) pathway, and the
activating transcription factor 6 (ATF6) pathway (Bravo et al., 2013). Upon
accumulation of unfolded proteins, BiP/GRP78 dissociate from PERK leading to its
activation (Bravo et al., 2013). Once activated, the PERK pathway phosphorylates
the alpha subunit of the eukaryotic translation initiation factor-2 (eIF2-a) which in turn
activates ATF4 with downstream activation of C/EBP homologous protein (CHOP)
among other factors (Bravo et al., 2013). Chronic activation of CHOP may then lead
to apoptosis (Zhou et al., 2015). IRE1α in turn must dissociate from BiP/GRP78 and
directly interact with unfolded proteins to be activated (Bravo et al., 2013). Once
activated IRE1α catalyzes splicing of the X-box-binding protein-1 (XBP1) mRNA,
which then activates several genes including ER degradation enhancing αmannosidase like protein 1 (EDEM) and other genes involved in ER protein
synthesis, vesicular trafficking, lipid biogenesis, and autophagy (Bravo et al., 2013).
Finally, ATF6 is normally retained in the ER through activation with BiP/GRP78 and
calreticulin, but during ER stress is transported to the Golgi apparatus on vesicles
where it is cleaved (Bravo et al., 2013). The N-terminal fragment is then translocated
to the nucleus where it promotes transcription of UPR genes such as the
transcription factors XBP1 and CHOP, and the chaperones GRP94 and BiP/GRP78
(Bravo et al., 2013).
Kruppel-like factor 4 (KLF4) is a one of a group of proteins, also including
OCT4, SOX2, and c-MYC, which together enable the re-programming of terminally
differentiated cells into pluripotent stem cells (Schuetz et al., 2011). KLF4 is a zinc-
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finger transcription factor belonging to the Sp/Klf family (Schuetz et al., 2011). In
SMCs, KLF4 acts through two key mechanisms: binding to the G/C repressor
element in several SMC contractile genes, including ACTA2, TAGLN and MYH11,
and inhibiting binding of SRF to CArG elements, to downregulate the expression of
SMC contractile genes (Shankman et al., 2015). Activation of KLF4 is tied to the
PERK pathway through ATF4, which has been shown to both promote transcription
of KLF4 and suppress the proteasomal degradation of KLF4 (Zhou et al., 2015).
Recent data from our lab have shown that cholesterol treatment activates the UPR
and this UPR drives cholesterol-induced phenotypic modulation of SMCs to
proatherogenic modulated SMCs, primarily through the PERK arm of UPR
(Chattopadhyay et al., 2020). Upregulation of macrophage-specific markers and a
large subset of fibroblast-specific markers was inhibited by co-treatment with both 4phenylbutyric acid (4-PBA), a general inhibitor of ER stress, and integrated stress
response inhibitor (ISRIB), a specific inhibitor of PERK signaling (Chattopadhyay et
al., 2020).
Unpublished data from our lab have demonstrated that cholesterol treatment
activates not only ER stress, but also cytosolic stress in SMCs. Cytosolic stress or
the heat shock response involves the activation of heat shock proteins (HSPs) to
mediate the refolding or degradation of damaged proteins, primarily by the
transcription factor heat shock factor 1 (HSF1) (Barna et al., 2018). When activated,
HSF1 becomes trimerized and phosphorylated before translocating to the nucleus
where it binds to conserved heat shock-responsive DNA elements (HSEs) (Barna et
al., 2018). HSF1 is regulated via a negative feedback loop through which several of
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the proteins it activates, including HSP70, HSP72, and HSP90, directly inhibit HSF1
through binding to its trimerization domain (Barna et al., 2018). The HSP chaperone
family have diverse roles in cellular function: HSP90 binds damaged proteins and
directs them to HSP60 and HSP70 for further processing, in addition to playing
diverse roles in signal transduction systems (Barna et al., 2018).
In addition to its role in heat shock response, HSP70 is also required for the
proper assembly of pericentriolar material (PCM) (Fang et al., 2019). PCM contains
hundreds of proteins including microtubule nucleating factors, signaling molecules
and cell cycle regulators in addition to the scaffold protein pericentrin (Fang et al.,
2019). Errors in the proper accumulation of PCM at the centrosome can lead to a
functionally compromised mitotic centrosome with multipolar or disorganized
spindles leading to mitotic arrest, aneuploidy and/or cell death (Fang et al., 2019).
HSP70 is phosphorylated by NEK6 targeting HSP70 to the mitotic spindle where it
cooperates with PCNT and CEP215, among other proteins, to ensure their proper
assembly at the mitotic centrosome (Fang et al., 2019).
Here we describe unique coronary artery pathology from two patients with
MOPDII. We go on to utilize a novel smooth muscle cell specific pericentrin knockout mouse to investigate the role of the ATR pathway and phenotypic modulation in
disease development. We show that PcntSMKO cells display activation of UPR and
cytosolic stress pathways associated with phenotypic modulation and atherosclerotic
phenotype in vivo.
Materials and Methods
Patient Tissue
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The study protocol was approved by the Institutional Review Board of the
University of Texas Health Science Center at Houston and the patient or family
members consented to these studies. Coronary artery tissue was obtained at
autopsy and stained with hematoxylin and eosin (H&E) and Movat pentachrome
stain, and immunostained with anti-SMA (Sigma 5228) and anti-CD68 antibodies.
Mouse Generation
All mouse experiments were carried out in accordance with institutional
guidelines at The University of Texas at Houston for the care and use of animals.
Embryonic stem cell clones in a C57BL/6 background with the targeted Pcnt allele
(EPD0724_5_F03, B04 and A03) were purchased from the European Conditional
Mouse Mutagenesis program (EUCOMM.org). The targeting vector was designed to
contain a 5391 bp 5' targeting arm, a Laz and a neo expression cassette which were
flanked by two Frt sites. In addition, it contained a 1499 bp mouse Pcnt fragment
(spanning exons 17 and 18) that were flanked by two loxP sites and a 4438 bp 3'
targeting arm allowing for Cre-mediated conditional deletion of the Pcnt gene
between exons 17 and 18 leading to an out-of-coding frame shift, generating a
premature stop codon and a loss-of-function allele (figure 3.2). The embryonic stem
cell clones were microinjected into C57BL/6 blastocysts. Male chimeric founder mice
were bred with albino C57BL/6 females. Male chimeric mice with proven germ line
transmission then bred into 129 SvEv FLPeR mice (stock #003946, Jackson Lab) to
remove the Frt-flanked LacZ and neo cassettes. The Pcntfl/fl were then crossed into
SMA-Cre-ERT2 mice in a 129SvEv background. Resulting Pcntfl/+, SMA-Cre-ERT2+/mice were crossed with Pcntfl/+ mice to produce Pcntfl/fl, SMA-Cre-ERT2 mice. For
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experiments, Pcntfl/fl, SMA-Cre-ERT2+/- males were crossed with Pcntfl/fl females to
produce a Mendelian ratio of 50% Pcntfl/fl, SMA-Cre-ERT2+/- and 50% Pcntfl/fl to use
as littermate controls.

Figure 3.2. Pcnt-flox mouse construct and resulting
cross into SMA-CreERT2 mice.
Smooth muscle cell explant and cell culture conditions and cholesterol exposure
Ascending and descending aortic smooth muscle cells were isolated from 6-8
week old Pcntfl/fl, SMA-Cre-ERT2+/- mice according to previously published methods
(Kwartler et al., 2016). In brief, 3-6 mice per an experiment were anesthetized with
an IP injection of 2.5% avertin. Once the mouse was sufficiently anesthetized, the
thorax was exposed, the lungs removed to expose the aorta and its branches.
Microdissection technique was then used to dissect out and clean the heart, aorta
and aortic branches. Further cleaning was done in DPBS under a dissecting
microscope to remove any fatty or connective tissue. Once sufficiently cleaned, the
ascending aorta including the carotid arteries were separated from the descending
aorta using a scalpel and placed in separate labelled containers in aorta biopsy
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storage media. Aortic and carotid artery tissue was isolated from 3-6 mice in this
manner, combining the ascending and descending aortic tissue from all mice into
their respective dishes.
Once all the tissue had been thoroughly cleaned, digestion media was
prepared, the tissue washed in ethanol briefly and then rinsed in PBS. The tissue
was cut into fragments for digestion and allowed to digest overnight. Once tissue
was digested with visible floating cells, tissue and cells were spun down and
transferred to a new 10 cm dish in smooth muscle basal medium (Promo Cell)
supplemented with 20% fetal bovine serum (FBS, Gibco), insulin, epidermal growth
factor, fibroblast growth factor (Promo Cell), HEPES (Millipore Sigma), sodium
pyruvate (Millipore Sigma), L-glutamine (Millipore Sigma), and antibiotic/anti-mycotic
(Millipore Sigma).
Free cholesterol complexed to methyl-β-cyclodextrin (MBD-Chol), containing
~40mg cholesterol per gram of product, was purchased from Millipore Sigma and
dissolved in deionized water. All calculations for cholesterol treatment were based
on the weight of cholesterol in the MBD-Chol complex. Explanted SMCs were
treated with 0, 2.5, and 10 μg/mL MBD-Chol (as described by Rong and colleagues)
in Dulbecco’s Modified Eagle Medium (DMEM) containing high glucose (Cellgro),
10% FBS (Gibco), 1% antibiotic/anti-mycotic (Millipore Sigma) and 0.2% bovine
serum albumin (BSA, Fisher Scientific) for 72 hours at 37C and 5% CO2.
Protein extraction and Western blot
For protein analysis, when cultured cells were confluent, cold lysis buffer was
prepared (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100 and 1mM EDTA)
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with protease inhibitor cocktail (Millipore Sigma) and phosphatase inhibitor cocktails
(Millipore Sigma). Cells were collected via scraping and incubated in lysis buffer for
15 minutes followed by 15 second sonication. Crude lysates were then cleared via
centrifugation at top speed for 10 minutes at 4 C. Bradford was performed per
protocol (BioRad Laboratories) and protein concentrations quantified. For pericentrin
60-80 μg of protein was resolved on a 4% gel (ProtoGel National Diagnostics). For
all other samples 10-30 μg of protein was resolved on 4-20% TGX gels (Bio-Rad
Laboratories). Protein was then transferred to PVDF membranes (Millipore Sigma),
blocked with 5% dry milk (or 5% BSA for detecting phosphorylated proteins, Atf4,
and pericentrin) in Tris-buffered saline (TBS), containing 0.05% Tween-20 (TBST)
and the membrane probed with different antibodies (Table 1). Bands were visualized
by chemiluminescent substrate (GE Healthcare) on a BioRad Imager. Band
intensities on the immunoblots were quantified using ImageJ software.
TABLE 3.1: List of antibodies used for Western blot
Target Antigen
α-smooth muscle actin (α-SMA)
Atf4
Atf6
α-Tubulin (DM1A)
Cdc2/Cdk1
Cdc25B
Cd68
Calponin (Cnn1)
Chk1
eIF2α

Vendor/Source
Millipore Sigma
Cell Signaling
Technologies
ThermoFisher Scientific
Cell Signaling
Technologies
Cell Signaling
Technologies
Cell Signaling
Technologies
Abcam
Thermo Fisher Scientific
Cell Signaling
Technologies
Cell Signaling
Technologies

Catalog #
A5228
11815S/D4B8
NBP14025601
CST 3873T
CST 77055
CST 9525
ab125212
PIMA511620
CST 2360S
5342S/D7D3
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Gapdh
Hsp70
Hsp90
Ire1α
Klf4
Lgals3
Pericentrin /Pericentrin-2
Phospho-Cdc2/Cdk1 (Tyr15)
Phospho-Cdc25B (Ser323)
Phospho-Chk1 (Ser345)
Phospho-eIF2α
Phospho-Ire1α (phospho S724)
SM22-α/TAGLN/transgelin
Smooth Muscle Myosin Heavy
Chain

Cell Signaling
Technologies

CST 14C10

Cell Signaling Technologies
Cell Signaling Technologies

CST 4872
CST 4874

Abcam
RnD Systems
Abcam
Abcam
Cell Signaling
Technologies
Abcam
Cell Signaling
Technologies
Cell Signaling
Technologies
Abcam
Abcam

ab37073

Abcam

ab76245/EP2775Y
ab4448
CST 4539
ab53103
CST 2348
3398S/D9G8
ab48187
ab14106
Ab53219

RNA extraction, quantitative real-time PCR (qPCR)
Total RNA was isolated from cultured SMC explants, quantified by Nanodrop
(Thermo Fisher Scientific), and then used for cDNA synthesis using QScript reagent
(Quantabio). mRNA expression for macrophage-specific and ER stress-specific
genes was estimated using SYBR green chemistry (primers were obtained from
Millipore Sigma and reaction master mix from Quantabio, Table 2) and for SMC
contractile genes using Taqman probes (Taqman probes were purchased from
Applied Biosystems and qPCR master mix obtained from Takara Biosciences).
Reactions were performed in triplicate. 18S rRNA and Gapdh were used as
endogenous controls for SYBR and Taqman reactions, respectively.
TABLE 3.2: List of SYBR primers used for quantitative real-time PCR (qPCR)
Gene

Forward primer (5’ -> 3’)

Reverse primer (5’ -> 3’)
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Cd68
Lgals3
Abca1
Klf4
Unspliced Xbp1
(uXbp1)
Spliced Xbp1
(sXbp1)
Atf4
Chop
Grp94
BiP
Edem
Hsf1
Hsp70
Hsp90aa1
Hsp90ab1
Serping1
Fn1
Ecrg4
(1500015O10Rik)
Fmod
Prg4
Spp1
Lcn2
Timp1

CAAGGTCCAGGGAGGTT
GTG
AGGAGAGGGAATGATGT
TGCC
GCGGACCTCCTGGGTGT
T
CTGAACAGCAGGGACTG
TCA
CAGCACTCAGACTATGT
GCA
CTGAGTCCGAATCAGGT
GCAG
GGGTTCTGTCTTCCACTC
CA
CCACCACACCTGAAAGC
AGAA
AAGAATGAAGGAAAAACA
GGACAAAA
TTCAGCCAATTATCAGCA
AACTCT
CTACCTGCGAAGAGGCC
G
GGACAGGAACAGCTCCT
TGA
CAGCGAGGCTGACAAGA
AGAA
AATGCTTAGAACTATTTA
CTGAACTAGCAGAA
GCGCACGCTGACTTTGG
T
GCCCAATTCGATGACCAT
AC
CGAGGTGACAGAGACCA
CAA
AAGCGTGCCAAACGACA
GCTGTGGGAC
CAACACCAACCTGGAGA
ATCTTT
GAAAATACTTCCCGTCTG
CTTGT
TCACCATTCGGATGAGTC
TG
TGCCACTCCATCTTTCCT
GTT
CCAGAGCCGTCACTTTG
CTT

CCAAAGGTAAGCTGTCC
ATAAGGA
GGTTTGCCACTCTCAAAG
GG
CAAGAATCTCCGGGCTTT
AGG
GTGTGGGTGGCTGTTCT
TTT
GTCCATGGGAAGATGTT
CTGG
GTCCATGGGAAGATGTT
CTGG
AAGCAGCAGAGTCAGGC
TTTC
AGGTGAAAGGCAGGGAC
TCA
CAAATGGAGAAGATTCC
GCC
TTTTCTGATGTATCCTCT
TCACCAGT
GTTCATGAGCTGCCCAC
TGA
TCCTGTTTCCCCTTCATC
AG
GGAGATGACCTCCTGGC
ACT
GTCCTCGTGAATTCCAAG
CTTT
CCTGGAGAGCCTCCATG
AAC
AAGTTGGTGCTTTGGGA
ACA
CTGGAGTCAAGCCAGAC
ACA
TTAATAGTCATCATAGTT
GACACTGGC
GTGCAGAAGCTGCTGAT
GGA
ACTCCATGTAGTGCTGAC
AGTTA
ACTTGTGGCTCTGATGTT
CC
GGGAGTGCTGGCCAAAT
AAG
AGGAAAAGTAGACAGTG
TTCAGGCTT
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Bgn

ATTGCCCTACCCAGAACT
TGAC
TTCCTACTCGGCTGTGA
GTC

Dcn

GCAGAGTATGAACCCTTT
CCTG
AAGTTGAATGGCAGAAC
GC

Immunofluorescent staining
Cover slips were irradiated and then plated with 10,000 to 20,000 cells each.
Cells were allowed to adhere overnight and then treated with 10 ng/ml TGF-β1 for
72 hours. Cells were washed in DPBS and fixed with 4% paraformaldehyde in 0.1M
phosphate buffer for 20 minutes. Cells were permeabilized in 0.3% TritonX-100 in
DPBS for 30 minutes and blocked in 2.5% BSA in DPBS plus 0.1% Tween20. Cells
were incubated in primary antibody (see Table 1) at 4 C overnight followed by
secondary antibody 1 hour at room temperature. Cells were incubated in 2.5%
Texas-Red-Phalloidin (Thermo Fisher Scientific) stain per protocol for 30 minutes at
room temperature. Coverslips were then mounted on slides using Vectashield with
DAPI (Vector Laboratories). Slides were imaged using a Leica DMi8 confocal
microscope.
BrdU incorporation cell proliferation assay
Assay performed per protocol (Cell Signaling Technologies). In brief, cells
were seeded in 96-well plate, 5,000-10,000 cells per well. Cells were allowed to
attach overnight then cells were serum starved for 24 hours followed by treatment
with 5 ng/ml PDGF-BB for 24 hours. Cells were then treated with BrdU for 24 hours
then fixed and incubated in primary and secondary antibodies per protocol.
Substrate was incubated for 30 minutes at room temperature and then absorbance
at 450 nm read.
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Wound healing migration assay
Cells were plated in a 12 well plate in triplicate and allowed to become
confluent. Once confluent, a wound was made using a 21G needle. The plate was
then rinsed with DPBS and placed in serum free media. Brightfield images were
captured on a Zoe Fluorescent Cell Imager (BioRad) at 175x magnification at 0 and
24 hours. Wound width was measured in ImageJ at three points per well and
averaged, and the percent wound closure averaged over three wells.
Klf4 transactivation assay
A Klf4 transactivation assay was performed using a Cignal Reporter Plasmid
(Qiagen) and the luciferase activity measured using a Dual Luciferase Reporter
Assay Kit (Promega) per the manufacturer’s instructions. In brief, 25,000 SMCs were
plated in triplicate on 24-well plates and transfected with 250 ng Klf4 Cignal Reporter
Plasmid (Qiagen) using Lipofectamine reagent (Life Technologies) for 4 hours. Cells
were then treated with or without cholesterol for 72 hours. Following incubation, the
cells were subjected to luciferase assay using a Dual Luciferase Reporter Assay Kit
(Promega) according to manufacturer’s instructions. Klf4 transcriptional activity was
quantified as the ratio between the luminescence from firefly luciferase and Renilla
luciferase.
Heat shock element luciferase assay
Heat shock element (HSE) luciferase assay was performed by transfecting
25000 SMCs (in triplicates) with 250ng HSE Cignal Reporter plasmid (Qiagen) using
Lipofectamine reagent (Life Technologies), followed by treating the cells with
cholesterol and finally measuring the firefly and Renilla luciferase luminescences
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using a Dual Luciferase Assay Kit (Promega), as per manufacturer’s instructions.
HSE luciferase activity, a measure of Hsf1 binding to the HSE, was expressed as
the ratio between the firefly and the Renilla luciferase luminescences.
Echocardiography
Echocardiography measurement (Vevo 3100 imaging system; MX550D, 40 MHz
transducer; VisualSonics, Toronto, Canada) was performed 2 weeks post-operation
(Zhou et al., 2019). Briefly, mice were weighed and anesthetized by 0.5 to 1.0 L/min
room air with 2% isoflurane via nose cone. The heart rate was closely monitored and
the body temperature was maintained around 38.5°C using the heating system.
Mouse aortic root and ascending aorta were imaged in B-mode. Left ventricular
function derived from short-axis parasternal planes was imaged using M-mode.
Three measurements were taken of maximal internal diameter at the aortic root and
ascending aorta. Left ventricular function measurements were gained from 3
different cardiac cycles and averaged. Data were analyzed by operator blinded to
the treatment groups.
AAV-PCSK9DYinjection and Oil Red O Staining
Six-week-old mice were injected with 1.1x109 viral particles via retroorbital injection.
They were allowed to recover for one week and then switched to a high fat diet (42%
from fat, Envigo) for 14 weeks. At the end of 14 weeks mice were weighed,
cholesterol measured, and blood collected. Mice were then sacrificed and the whole
aorta, from aortic root to iliac bifurcation was collected and the outside thoroughly
cleaned. The aorta was then opened and pinned en face and Oil Red O staining
performed per protocol. Pictures were then taken and the images analyzed using
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ImageJ. For image analysis, the whole aortic area was measured followed by the
area of Oil Red O staining. The percent lesion was calculated by taking the lesion
area and dividing by the total aortic area and multiplying by on-hundred.
Results
Atherosclerotic disease in patients with MOPDII
Coronary artery tissue was obtained from two siblings with MOPDII who both
died of complications of vascular diseases. Patient 1 had a past medical history of
kidney transplantation for chronic kidney disease, bilateral bypass revascularization
for moyamoya disease, and clipping of a left vertebral artery aneurysm. He did have
hypertension and hypercholesterolemia. Patient 1 suffered a lethal myocardial
infarction and died at the age of 25 years.
Patient 2 was the sister of patient 1 who had MOPDII. She had a past
medical history of stage IV chronic kidney disease, tracheomalacia status post
tracheostomy, asthma, diastolic cardiac dysfunction, and multilevel coronary artery
disease. During a paraesophageal hernia repair she suffered an acute ischemic
stroke in addition to developing a klebsiella urinary tract infection leading to acute
kidney disease requiring dialysis. This was further complicated by additional
myocardial infarction, sepsis, and acute respiratory distress syndrome.
At autopsy, patient 1 was found to have severe stenotic coronary
arteriopathy, with both the left and right coronary arteries showing variable degrees
of fibromuscular intimal thickening and associated atheromatous changes. The
proximal to mid right coronary artery had complete stenosis with superimposed
thrombus. The proximal to mid left anterior descending coronary artery had marked
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stenosis also with a superimposed thrombus. There were extensive areas of
myocardial infarction involving both the left and right ventricle and the interventricular
septum most prominent in the posterior and lateral walls of the left ventricle.
Histologic examination revealed large atheromatous plaques containing SMCs,
calcification, and cholesterol crystals surrounded by macrophages, loss of cells in
the medial layer and increased elastosis in the adventitial layer (figure 3.3).
Immunostaining of a SMC marker, smooth muscle α-actin, revealed increased
numbers of positive staining cells in the adventitial layer but few vacuolated SMCs in
the medial layer.
At autopsy, patient 2 was also found to have a stenotic coronary arteriopathy,
with 90% occlusion of the right coronary artery, and 30% occlusion of the left main,
left anterior descending and left circumflex coronary arteries. There was evidence of
multiple prior myocardial infarctions involving the posterior-lateral left ventricle and
posterior interventricular septum with patchy interstitial fibrosis throughout the right
ventricle, posterior interventricular septum, and posterior-lateral left ventricle with
associated myocyte hypertrophy. The aortic arch had numerous calcifications and
the descending aorta showed medial calcification and intimal hyperplasia.
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Figure 3.3. Left anterior descending coronary artery from MOPDII patient 1.
Low magnification image of Movat staining (a) reveals a large atherosclerotic
plaque (P) in the left anterior descending coronary artery with a small residual
lumen (L). Higher magnification image (b, c) of the artery wall (A) shows a
well-formed internal elastic lamina (c, arrow) with an absence of cell staining in
the medial layer (M) and elastosis in the adventitial layer (Ad). Hematoxylin
and eosin staining (d-f) shows these findings along with cholesterol crystals in
the atherosclerotic plaque. Alpha-smooth muscle actin (SMA) staining reveals
large numbers of SMA-positive cells in the adventitia and fibrous cap (g, h) of
the atherosclerotic plaque, while confirming an absence of SMA-positive cells
in the medial layer (i). Finally, staining for the macrophage marker CD68
reveals staining in the atherosclerotic plaque (j), and CD68-positive cells within
the fibrous cap (k, l).
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Figure 3.4. Left main coronary artery bifurcation of MOPDII patient 2. The low
magnification image of the Movat staining (a) reveals a large atherosclerotic
plaque (P) with residual lumen (L). Higher magnification images of the artery
wall (A) reveal an absence of cells in the medial layer (M) and elastosis (b, c).
H&E staining (d-f) shows similar changes. While SMA staining shows SMApositive cells in a portion of the artery wall (g) and in the fibrous cap (h, solid
box) with a paucity of SMA-positive cells in other areas of the artery wall (i,
dashed box).
Histology examination was similar in that the proximal right coronary artery
contained an occlusive atheromatous plaque with extensive calcification, cholesterol
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crystals and SMCs, loss of medial SMCs in the region of the plaque and positive
staining cells in the adventitial layer (figure 3.4).
Smooth muscle cell specific pericentrin knock-out mouse
A pericentrin smooth muscle cell specific knock-out mouse line in which a
mouse carrying flox sites flanking exon 17 and 18 of Pcnt was obtained and crossed
into a SMA-Cre-ERT2 mouse line. The resulting offspring were Pcntfl/fl, SMA-CreERT2 (PcntSMKO), where treatment with tamoxifen in vivo or 4-hydroxy-tamoxifen in
vitro in turn resulted in an out-of-coding frame shift, generating a premature stop
codon and a loss-of-function allele (figure 3.5a). We confirmed deletion of pericentrin
in isolated SMCs with a 50% reduction in pericentrin on immunoblot analyses (figure
3.5b, c).
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Figure 3.5. Construct of Pcnt-flox mouse and confirmation of reduction in
pericentrin expression. Pcntfl/fl mice containing loxP sites flanking exon 17
and 18 of Pcnt were crossed into smooth muscle (SM) actin-Cre-ERT2 mice
leading to a premature stop codon and loss of function allele when treated
with 4-hydroxytamoxifen (4-OHT, a). A reduction in pericentrin expression was
confirmed with Western blot (b) and quantified (c).
The PcntSMKO SMCs were harvested with and without exposure to TGFβ and
SMC differentiation markers assessed and the mutant SMCs had similar levels of
SM α-actin, SM myosin heavy chain (SMMHC), calponin and SM22α (figure 3.6a).
Immunofluorescent staining of α-actin filaments revealed that PcntSMKO SMCs
formed organized and intact actin filaments similar to the control SMCs (figure 3.6b).
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Figure 3.7. PcntSMKO (Pcntfl/fl+4OHT) cells display increased proliferation and
migration compared to DMSO treated control cells. BrdU incorporation assay
shows increased proliferation of PcntSMKO cells when treated with the SMC
mitogen TGF-β (a). Wound healing scratch assay reveals increased migration
of PcntSMKO (KO) cells compared to control as seen by % closure (a, b).
Activation of ATR-Chk1 in PcntSMKO cells
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All the current hypothesis for the pathogenesis of the disease phenotype in
patients with MOPDII are centered around a reduction in cellular proliferation (i.e.
spindle cell misorientation, mitotic defects, ATR-Chk1 cell cycle inhibition) (Delaval
and Doxsey, 2010; Chen et al., 2014a). Pericentrin plays a key role in ATR cell cycle
regulation through the aiding of microcephalin recruitment of p-Chk1 to the
centrosome, where p-Chk1 then acts to phosphorylate Cdc25B, deactivating it, and
thus inhibiting G2 to M cell cycle progression through the accumulation of
phosphorylated Cdk1/Cyclin B.
The ATR-Chk1 pathway is activated in response to oxidized cholesterol, 7ketocholesterol, therefore we assessed whether the ATR-Chk1 pathway was
activated in PcntSMKO cells at baseline and in response to the cholesterol complexed
to methyl-β-cyclodextrin (MBD-Chol) (Chang et al., 2016). To do so we assessed
several proteins in this pathway in PcntSMKO and control cells at baseline and with
exposure to 2.5 or 10 μg/ml of MBD-Chol. Total Chk1 was increased at baseline in
PcntSMKO cells compared to controls and was further increased with 2.5 μg/ml MBDChol with corresponding elevation in p-Chk1 at baseline and with low levels of MBDChol (figure 3.8). This suggests that the ATR-Chk1 pathway is activated in PcntSMKO
cells at baseline and with low levels of cholesterol treatment. In turn, both total
Cdc25B and p-Cdc35B was reduced in PcntSMKO cells at baseline and with low levels
of cholesterol suggesting downregulation of phosphorylation of Cdc25B by Chk1 in
PcntSMKO cells. Finally, both total Cdk1 and p-Cdk1 are elevated in PcntSMKO cells
compared to controls at baseline and with low levels of cholesterol suggesting that
Cdk1 may be driving G2/M cell cycle progression in the absence of pericentrin.
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Figure 3.8. Activation of the ATR-Chk1 pathway in PcntSMKO SMCs. Western
blot analysis of 4OHT treated PcntSMKO cells (a) shows increased activation
of the ATR pathway at baseline and with cholesterol treatment with a
reduction in p-Cdc25B compared to control cells and an increase in both
total and p-Cdk1 (c). Protein expression of various ATR-Chk1 pathway
proteins show increased expression at baseline and with cholesterol
treatment in PcntSMKO SMCs compared to controls. The reduction in pCdc25B in PcntSMKO SMCs suggests that p-Chk1 is not localizing to the
centrosome as hypothesized.
PcntSMKO cells undergo phenotypic modulation when exposed to cholesterol
Our previous studies found that exposing SMCs to free cholesterol
complexed to β-cyclodextrin cholesterol (MBD-chol) activates ER stress and a global
unfolded protein response (UPR), which modulates the SMC phenotype that
resembled modulated SMCs that appear with progression of atherosclerosis. The
atherosclerosis-associated modulated SMC phenotype is characterized by
decreased expression of SMC differentiation markers, and increase expression of
fibroblast, macrophage and stem cell markers. We sought to determine if the
PcntSMKO SMCs upregulated atherosclerosis-associated markers of a modulated
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SMC similar to control cells. PcntSMKO SMCs and WT SMCs were exposed to
varying levels of MD-chol. Interestingly, we found that the contractile markers Acta2,
Tagln, and Cnn1 were downregulated in PcntSMKO SMCs with exposure to 2.5 ug/ml
of MBD-Chol treatment whereas the WT SMCs did not downregulate these SMC
markers until exposed to 10 ug/ml MD-chol (figure 3.9a). Furthermore, PcntSMKO
SMCs also upregulated macrophage markers Cd68 and Lgals3 with low levels of
cholesterol treatment whereas the WT SMCs did not (figure 3.9b). Immunoblot
analyses confirmed these findings (figure 3.9c).

Figure 3.9. 4OHT treated PcntSMKO cells display phenotypic switching. SMC
contractile markers, Acta2, Tagln, and Cnn1, are downregulated in Pcnt SMKO
cells with low levels of cholesterol treatment compared to controls (a). While
macrophage markers, Cd68 and Lgals3, are increased in PcntSMKO cells
compared to DMSO treated control cells (b). These findings were confirmed
by Western blot showing increased Cd68 and Lgals3 expression with
decreased α-SMA and Cnn1. * or ** : p < 0.05 or p < 0.01, vs no cholesterol. #
or ## : p < 0.05 or p < 0.01, DMSO vs 4-OHT.

62

In addition to modulated SMCs adopting a macrophage-like phenotype, have
also been found to adopt a fibroblast- and mesenchymal stem cell-like phenotype.
To assess phenotypic modulation to a fibroblast-like cell phenotype we looked at
several fibroblast cell markers and found that many of them were upregulated at
baseline in PcntSMKO, in the absence of cholesterol treatment (figure 3.10), including
Fbn1, Ecrg4, Fmod, Prg4, Spp1, Timp1, Bgn, Dcn, and Serping1. In addition, the
mesenchymal stem cell marker Sca1 was also upregulated at baseline and with
cholesterol treatment.

Figure 3.10. PcntSMKO cells undergo phenotypic modulation to a fibroblast- and
mesenchymal-like state. Several fibroblast markers are upregulated in 4OHTtreated PcntSMKO cells at baseline (Fn1, Ecrg4, Fmod, Prg4, Timp1, Bgn, Dcn,
and Serping1) and in response to cholesterol treatment (Fn1, Ecrg4, and
Spp1). In addition, the mesenchymal stem cell marker Sca1 is also increased
at baseline and in response to cholesterol treatment. * or ** : p < 0.05 or p <
0.01, vs no cholesterol. # or ## : p < 0.05 or p < 0.01, DMSO vs 4-OHT.

Phenotypic modulation has been shown to be mediated through the UPR
(Chattopadhyay et al., 2020). To investigate this potential mechanism for phenotypic
modulation in PcntSMKO cells we assess markers for the three branches of the UPR:
Perk, Atf6, and Ire1α (figure 3.11). Activation of the Perk pathway was indicated by
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elevation of Atf4 in presence of low levels of cholesterol, although Chop, another
downstream product of the Perk pathway, was not significantly elevated compared
to control. In addition to activation of the Perk pathway, there was also evidence of
activation of the Atf6 arm of the UPR as evidenced by elevations in both Grp94 and
Bip in PcntSMKO cells in the presence of low levels of cholesterol. Finally, the Ire1a
pathway was also activated as seen by increased levels of Edem in PcntSMKO cells in
the presence of low levels of cholesterol in conjunction with increased sXbp1.

Figure 3.11. PcntSMKO cells show activation of Unfolded Protein Response
(UPR) pathways. Atf4, Grp94, Bip, and Edem are all upregulated in response
to low levels of cholesterol (a) suggesting activation of all three UPR
pathways. sXbp1 is also elevated with cholesterol (b) suggesting activation of
Ire1α. In addition, p-Ire1α is elevated on Western blot (c). While there is no
difference in Klf4 activation between 4OHT-treated PcntSMKO cells and
DMSO-treated control cells (d). * or ** : p < 0.05 or p < 0.01, vs no cholesterol. #
or ## : p < 0.05 or p < 0.01, DMSO vs 4-OHT.
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Unpublished data from our laboratory has shown activation of cytosolic stress
pathways in modulated SMCs. With this in mind, we assessed cytosolic stress in the
PcntSMKO cells to identify if this may also be driving phenotypic modulation in these
cells. Interestingly, the heat shock transcription factor Hsf1, and all three heat shock
gene transcripts examined, Hsp70, Hsp90aa1, and Hsp90ab1, were significantly
upregulated at baseline (figure 3.12a). This was confirmed by Western blot analysis
of Hsp90 and Hsp70 which were also upregulated at baseline, prior to cholesterol
treatment in PcntSMKO cells (figure 3.12c). Finally, we assessed activation of the heat
shock element by Hsf1 using a dual luciferase activity assay and found that HSE
activation was up at baseline and with low levels of cholesterol treatment in PcntSMKO
mice compared to controls (figure 3.12b). These findings suggest that PcntSMKO cells
undergo phenotypic modulation at a higher rate than controls at low levels of
cholesterol and that this modulation is due to activation of the UPR and/or cytosolic
stress.
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Figure 3.12. Cytosolic stress pathways are significantly elevated at
baseline in 4OHT-treated PcntSMKO SMCs compared to DMSO-treated
control cells. The heat shock transcription factor, Hsf1, along with the heat
shock proteins Hsp70, Hsp90aa1, and Hsp90ab1 are all elevated at
baseline in PcntSMKO cells (a). Hsf1 activation of heat shock element
(HSE) is also increased at baseline and with cholesterol treatment in
PcntSMKO cells (b). Finally, these findings were confirmed by Western blot
with both Hsp70 and Hsp90 having increased protein expression at
baseline in PcntSMKO cells (c).
PcntSMKO mice do not have aortic dilatation or alterations in cardiac output
Echocardiography was performed and aortic and cardiac parameters
evaluated. No aortic enlargement was observed in PcntSMKO mice compared to
controls, either at the aortic root or the ascending aorta (figure 3.13 a-c). Cardiac
output was also unchanged in PcntSMKO mice compared to controls (figure 1.13d).
Consistent with this finding there was also no significant difference in systolic or
diastolic cardiac diameter and left ventricular volume, or ejection fraction.
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Figure 3.13. PcntSMKO mice do not have aortic dilatation or cardiac dysfunction
on echocardiography. There was no significant differences in aortic sinus or
ascending aortic diameter (a-c) or cardiac output (d) on echocardiography.
PcntSMKO mice develop atherosclerotic disease in vivo
To study the development of atherosclerotic disease in vivo we utilized a
constitutive SM22α-Cre in conjunction with our Pcnt-flox mice to enable knock-out of
Pcnt from the beginning of development. Studies have shown that a single injection
of adeno-associated virus (AAV) expressing a gain-of-function mutation in PCSK9
(PCSK9DY) leads to sustained hypercholesterolemia when the mice are fed a high
fat diet, and the subsequent atherosclerotic plaque burden is similar to that observed
in the Ldlr-/- mice with a similar diet (Roche-Molina et al., 2015). We injected 6-weekold mice with AAV-PCSK9DY and then fed a high fat diet for 14 weeks. En face whole
aorta Oil Red O staining showed significantly more atherosclerotic disease in the
Pcntfl/fl, SM22α-Cre mice compared to Pcntfl/fl control mice (figure 3.14). It should be
noted that two outlying values, one per group, were excluded due to possible
overstaining. With these values included the difference in staining between the
groups was not statistically significant. There was no statistically significant
difference in weight or cholesterol level.
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Figure 3.14. Atherosclerotic disease in PcntSMKO mice following AAVPCSK9DY and high fat diet. Representative Oil Red O stained whole aortas
from mice administered a single injection of AAV-PCSK9DY and fed high fat
diet for 14 weeks (a). Oil Red O staining was quantified in ImageJ and the
percent lesion was calculated (b). PcntSMKO mice had significantly more
atherosclerotic disease burden compared to control mice (p=0.0479).
Weights were measured prior to aorta collection. There was no significant
difference in weight between PcntSMKO and control mice (c). Non-fasting
cholesterol level was measured prior to sacrifice (maximum measurement
300). There was no significant difference in cholesterol level between
PcntSMKO and control mice (d).
Discussion
Here we describe coronary artery pathology from two patients with MOPDII.
These patients have a particularly severe atherosclerotic phenotype given their
young age. While patient 1 did have a history of hypercholesterolemia and
hypertension, the degree of coronary artery disease seen is out of proportion to his
relatively young age and absence of other risk factors such as smoking,
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hypertension, diabetes mellitus, and obesity (Herrington et al., 2016). In addition to
the severe atherosclerotic disease in these patients were changes not commonly
seen with atherosclerosis, particularly the loss of SMCs within the medial layer.
Human coronary arteries normally have multiple layers of SMCs, but the coronary
arteries of both patients presented here showed a marked reduction in SMCs in the
medial layer, with greater than expected numbers of SMA-positive cells in the
adventitial layer and a population of SMA-positive cells in the fibrous cap of the
atherosclerotic plaques (Sharma et al., 2017).
There are a few possibilities for the marked reduction in SMCs in the medial
layer, the first being abnormalities in artery development. SMCs are recruited to the
endothelial layer during artery wall development through PDGFB signaling (Udan et
al., 2013). Alterations in the recruitment would explain the paucity of SMCs in the
medial layer but not the presence of SMA-positive cells within the adventitia and
fibrous cap. Another possibility is that SMCs originally migrate to the medial layer
and then due to factors yet to be determined, migrate out from the medial layer to
the adventitial layer and fibrous cap of the atheroma, explaining the large numbers
of SMA-positive cells in these locations. Finally, another possibility is that while
some SMCs migrate into the atheroma and fibrous cap, some SMCs remain behind
and become apoptotic. The SMCs present in the medial layer were noted to appear
vacuolated and “sick”. This raises the possibility that those SMCs remaining in the
medial layer are abnormal and undergo apoptosis at a high rate, while SMCs that
migrate out of the medial layer and undergo phenotypic modulation have a survival
advantage.
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Also of note in MOPDII patient coronary arteries is the degree of elastosis in
the adventitial layer. The proximal coronary arteries are muscular and therefore
typically contain to elastin layers, the internal and external elastic laminae, with the
external elastic lamina being absent in the smallest of the muscular arteries
(Cocciolone et al., 2018). The elastin precursor, tropoelastin, is primarily produced
by SMCs within the media, but may also be produced by endothelial cells in the
intima and fibroblasts in the adventitia (Cocciolone et al., 2018). The elastin
deposition within the adventitial layer may be produced by either SMCs or
myofibroblasts.
The increased proliferation observed by PcntSMKO SMCs was surprising given
that all of the currently posited hypothesis for the clinical manifestations of MOPDII
are centered around decreased cellular proliferation (Griffith et al., 2008; Delaval
and Doxsey, 2010; Chen et al., 2014b). Here we investigate a potential role for the
ATR-Chk1 pathway in increased SMC proliferation. Of note, total Cdk1 was found to
be increased in PcntSMKO SMCs in addition to p-Cdk1. Increased Cdk1 is observed in
multiple cancers suggesting a role in abnormal cellular proliferation (Hansel et al.,
2005; Kang et al., 2014; Yang et al., 2014; Zhang et al., 2018).
All three ER stress pathways, Perk, Atf6, and Ire1a, are activated with low
levels of cholesterol treatment in PcntSMKO SMCs. In addition, the heat shock
response pathway is upregulated at baseline and with low levels of cholesterol
treatment. Cholesterol-induced phenotypic switching has been shown to be
associated with UPR activation with inhibition of the UPR preventing phenotypic
switching in SMCs (Chattopadhyay et al., 2020). Hsp70 is known to interact with
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Pcnt at the centrosome (Fang et al., 2019). One potential hypothesis for activation of
the heat shock response at baseline in PcntSMKO SMCs is that absence of the
scaffold function of pericentrin at the centrosome leads to activation of the heat
shock response. This would explain the increased activation of the heat shock
response at baseline. Hsp70 in turn negatively regulated Hsf1, a potential
mechanism for the decrease in heat shock response with cholesterol treatment.
The heat shock response is also linked to the ATR-Chk1 pathway. Treatment
with the heat shock protein inhibitor phenethyl isothiocyanate (PEITC) reduced
levels of CDK1 leading to G2/M cell cycle arrest and apoptosis in a human breast
cancer cell line in addition to reducing levels of HSF1, HSP70 and HSP90 (Sarkars
et al., 2013). This suggests a link between the heat shock response and CDK1mediated G2/M checkpoint regulation. This makes PEITC a potentially promising
pharmacologic treatment for the inhibition of both the ATR-Chk1 pathway and the
heat shock response in MOPDII.
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Chapter Four: Discussion
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The study of rare genetic disorders such as SMDS and MOPDII are crucial
not only to our understanding of their pathophysiology and to the development of
better treatments for these conditions, but also to our understanding of more
common conditions. Vascular diseases are complex, but by studying rare conditions
in which vascular pathology is prevalent and severe we may then better understand
the more common types of vascular pathology leading to coronary artery disease,
aortic aneurysm, cerebral infarcts, and Moyamoya disease just to name a few of
these diverse vascular pathologies.
Vascular smooth muscle cells are particularly unique in their ability to dedifferentiate and, as we discuss here, modulate their phenotype in response to
stimuli. Better understanding this process, what causes it, and how it contributes to
the development of disease helps us to understand the pathophysiology of vascular
disease. This in turn furthers the development of novel therapeutics for these
conditions.
Smooth Muscle Dysfunction Syndrome
Here we described hepatic and pulmonary pathology in three patients with
SMDS, including expansion of the portal triads, thickening of the terminal branches
of the hepatic artery, arterial changes consistent with pulmonary hypertension, and
emphysematous changes suggestive of abnormal pulmonary development. To
further study the pathogenesis of vascular disease associated with mutations in
ACTA2 R179 our laboratory developed a novel mouse model. Using this mouse
model, we can evaluate the lung histology and multiple time points from embryonic
development into adulthood to determine if the pulmonary changes observed in the
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three patients with SMDS also occur in the mouse model and whether these
changes are developmental in origin. We can also further characterize the liver
changes observed in patients with SMDS by studying the liver histology using this
mouse model along with the expression of specific cells, particularly SMAexpressing stellate cells. These findings suggest a crucial role for SMCs in lung
alveolar development and may shed light on other diseases of the lung parenchyma,
including other causes of emphysema and cystic lung disease.
In addition, using SMCs isolated from Acta2 R179 mutant mice, we can study
their phenotype in vitro, including contractile protein expression, proliferation, and
migration. Furthermore, we can assess whether these mutant cells undergo
phenotypic modulation when exposed to cholesterol similar to PcntSMKO and other
cell lines our laboratory is studying. Based on the pathology observed in the patient
samples from patients with SMDS described here we would expect to see increased
proliferation and migration of the mutant cells in vitro. These patients do not have a
higher rate of atherosclerotic disease, as seen in other models which undergo
phenotypic modulation, so we would not expect phenotypic modulation with
cholesterol treatment in these cells.
Majewski Osteodysplastic Primordial Dwarfism Type II
The studies of the coronary artery tissue from patients with MOPDII brought
up several interesting questions that our laboratory can continue to pursue. One
question is whether the findings we observed in the coronary artery tissue, including
dropout of SMCs in the medial layer, increased SMA positive cells in the adventitia,
and elastosis in the adventitia are specific to the coronary vascular bed. If similar

74

pathology is present in other arteries, that would suggest a unifying mechanism for
the diverse vascular pathologies observed in patients with MOPDII, including aortic
and cerebral aneurysms, and moyamoya disease.
In addition, the cause of dropout of SMCs in the medial layer of the coronary
arteries is yet to be elucidated. Histology of vessel tissue from PcntSMKO mice may
shed light on this by determining if this finding is recapitulated in the context of
smooth muscle cell-specific knock-out of pericentrin. If so, we can then assess the
presence and location of SMCs in the vessel wall during development and perform
apoptosis assays to determine if this finding is a result of decreased SMC
development, increased SMC cell death, or dysregulated cell migration. In addition,
it would be insightful to determine whether arteries from PcntSMKO mice show
increased elastin deposition like that observed in the MOPDII patient coronary artery
tissue.
Another question that still needs to be more fully explored is the exact role of
the ATR-Chk1 pathway in patients with MOPDII. Our findings show an increase in
ATR activation with a corresponding increase in Cdk1 and p-Cdk1 levels. Cdk1
levels typically do not vary widely, but overexpression has been observed in some
cancers, including melanomas and diffuse large B-cell lymphomas (Roskoski, 2019).
Further, data from other labs have shown a relationship between the heat shock
response pathway and Cdk1 cell cycle regulation (Sarkars et al., 2013). Finally,
Cdk1 has been shown to enhance protein synthesis at least in part through eIF2α
(Haneke et al., 2019). These findings suggest that Cdk1 may be a potential target for
inhibition of the increased proliferation observed in PcntSMKO SMCs. Several agents
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with inhibitory effects on Cdk1 have been developed for cancer therapeutics,
although none are specific to Cdk1 alone (Lin et al., 2009; Parry et al., 2010; Paruch
et al., 2010; Zeidner et al., 2015; Roskoski, 2016). These agents should be tested to
determine if inhibition of Cdk1 activity reduces proliferation in PcntSMKO SMCs.
All three pathways of the UPR were activated in PcntSMKO SMCs with low
levels of cholesterol. Previous studies in our laboratory in wild-type SMCs have
shown that phenotypic modulation is dependent on activation of the UPR
(Chattopadhyay et al., 2020). To further investigate the role of each UPR pathway in
phenotypic modulation of PcntSMKO SMCs the next step would be to treat them in
vitro with agents targeting the UPR. To delineate the specific UPR pathways
involved in phenotypic modulation of PcntSMKO SMCs, we would treat with the
integrative stress response inhibitor ISRIB, which blocks phosphorylation of eIF2a
and the downstream activation of ATF4, Ceapin A7 to inhibit the cleavage and
activation of ATF6, and finally Kira6 for the inhibition of Ire1α (Palam et al., 2015;
Mahameed et al., 2019; Xue et al., 2021). Based on the current data, we expect that
all three UPR pathways are involved in phenotypic modulation of Pcnt SMKO SMCs
with inhibiting one or all of these pathways leading to alteration of phenotypic
modulation.
Finally, next steps would also be to investigate the role of cytosolic stress in
phenotypic modulation in PcntSMKO SMCs. As shown in chapter 3, Hsf1, Hsp70, and
Hsp90 are all upregulated at baseline in PcntSMKO SMCs suggesting cytosolic stress
in these cells at baseline and with low levels of cholesterol. Additionally, Hsp70 is
known to interact with pericentrin at the centrosome, suggesting that loss of function
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mutations in Pcnt drive cytosolic stress through Hsp70. To investigate this further,
we should go on to treat PcntSMKO SMCs with cytosolic stress inhibitors and
determine the effect on SMC phenotypic modulation, proliferation, and migration.
These inhibitors should include 17-allyloamino-17-demethoxygeldanamycin (17AAG), a selective inhibitor of Hsp90 and Phenethyl isothiocyanate (PEITC), which
downregulates expression of Hsf1 in addition to inhibiting Cdk1 which, as discussed
previously, is also upregulated at baseline in PcntSMKO SMCs (Sarkars et al., 2013).
Conclusion
Here we have discuss novel insights into Smooth Muscle Dysfunction
Syndrome and Majewski Osteodysplastic Primordial Dwarfism Type II. Mutations in
ACTA2 lead to diverse, widespread vascular disease, including occlusive vascular
pathology (Guo et al., 2009; Papke et al., 2013). In addition to the known vascular
pathology caused by mutations in ACTA2 R179, we also found pulmonary
developmental abnormalities likely due to loss of ACTA2 expression in SMCs during
pulmonary segmental branching morphogenesis (Danopoulos et al., 2018; Goodwin
et al., 2019). In addition, these patients display thickening of the terminal branches
of the hepatic artery and expansion of the portal triads. As discussed, these findings
suggest multiple avenues for future research utilizing our Acta2 R179 mouse model.
Here we also describe how SMC-specific knockout of pericentrin leads to
increased SMC proliferation and migration. This may be due in part to dysregulation
of the ATR-Chk1 pathway as a result of loss of pericentrin leading to increased
Cdk1. We also found that loss of pericentrin leads to phenotypic modulation of
SMCs when exposed to cholesterol with decreased expression of SMC markers and
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increased expression of macrophage, fibroblast and mesenchymal stem cell
markers. All three of these cellular behaviors underly occlusive vascular disease
pathogenesis.
This work expands our understanding of rare vascular disease pathogenesis
and provides novel avenues for future scientific study. This includes further study of
the impact of the Acta2 R179 mutation on pulmonary development. There is also
potential for the use of Cdk1 or Hsf1 inhibitors in the management of MOPDII. These
findings also suggest a potentially pivotal role for ATR-Chk1 cell cycle regulation in
SMC proliferation and show further evidence of phenotypic modulation in
atherosclerotic disease development.
There are still multiple avenues of future research to be explored based on
these findings, including both in vitro and in vivo studies using pathway-specific
inhibitors as described above. These findings could eventually contribute to novel
therapies for the prevention of vascular disease development in patients with SMDS
and MOPDII. In addition, these findings broaden our knowledge of the role of
phenotypic modulation in vascular disease pathogenesis and potential avenues for
new therapies for atherosclerotic vascular disease.
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